UNRAVELLING THE ESSENTIAL ROLE OF TGPA IN THE VIABILITY OF PSEUDOMONAS AERUGINOSA: A PUTATIVE TARGET FOR NOVEL ANTIMICROBIAL AGENTS by M.M. URUBURU GOMEZ
                                                                                              
 
 
 
UNIVERSITÀ DEGLI STUDI DI MILANO 
PhD Course in Molecular and Cellular Biology 
XXIX Cycle 
 
 
 
 
Unravelling the essential role of TgpA in the viability of  
Pseudomonas aeruginosa: a putative target for novel antimicrobial agents 
 
 
 
 
Mónica Uruburu 
PhD Thesis 
 
 
 
 
Scientific tutor: Prof. Giovanni Bertoni 
 
Scientific co-tutors: Mario Milani & Eloise Mastrangelo 
 
 
 
Academic year: 2016-2017 
 
 SSD: BIO/19, BIO/10 
 
 
Thesis performed at Department of Biosciences, Università degli Studi di Milano. 
 
 
 
 
 Contents 
 
A. ABSTRACT .................................................................................................................... 1 
 
PART I 
 
B. STATE OF THE ART ...................................................................................................... 4 
B.1 Pseudomonas aeruginosa  ........................................................................................ 4 
B.1.1 Clinical importance  ................................................................................................. 5 
B.1.2. P. aeruginosa pathogenesis and virulence factors................................................. 7 
B.3. Antibiotic resistance in P. aeruginosa  .................................................................... 10 
B.3.1. Intrinsic resistance mechanism  ........................................................................... 10 
B.3.2. Mechanism of acquire resistance  ........................................................................ 11 
B.3.3. Adaptative resistance mechanism  ...................................................................... 13 
B.4. Multidrug resistance P. aeruginosa  ........................................................................ 15 
B.5. The crucial role of antibiotics  ................................................................................. 18 
B.5.1. Classic antibiotic targets  ..................................................................................... 19 
B.6. The urgent need for new antimicrobials  ................................................................. 22 
B.6.1. Novel essential genes as antimicrobial targets  ................................................... 23 
B.6.2. P. aeruginosa essential genes as antimicrobial targets  ...................................... 24 
B.7. Transglutaminase Protein A - TgpA, a novel essential protein in P. aeruginosa  .... 26 
B.7.1. Transglutaminases  .............................................................................................. 28 
B.7.2. Transglutaminases-like superfamily of enzymes  ................................................. 30 
B.7.3. Prokaryotic proteins with TG domain  .................................................................. 30 
B.7.3.1. Pseudomurein endoisopeptidases PeiW and PeiP  .......................................... 30 
B.7.3.2. WbmE of Bordetella bronchiseptica  ................................................................. 32 
B.7.3.3. AdmF, transglutaminase involved in the synthesis of Andrimid  ....................... 32 
B.8. Bacteria cell wall and peptidoglycan structure ........................................................ 33 
B.8.1. P. aeruginosa peptidoglycan structure.………………………………………………34 
B.8.2. Peptidoglycan synthesis  ..................................................................................... 34 
B.8.3. Peptidoglycan turnover and recycling  ................................................................. 36 
 
 C. Aim of the work  .......................................................................................................... 38 
 
D. Main Results  ............................................................................................................... 39 
D.1 Evaluation of the impact of mutations that knock-down TgpA activity on the growth of 
P. aeruginosa in different genetic systems  .................................................................... 39 
D.2. Structural characterization of the TG domain  ........................................................ 45 
D.2.1. Expression and purification of the TG domain  .................................................... 45 
D.2.2. Solving the structure of the periplasmic TG domain  ........................................... 47 
D.2.2.1. N-terminal portion: a regulatory domain?  ......................................................... 50 
D.2.2.2. TG domain active site  ...................................................................................... 54 
D.2.3. In vitro activity assays  ......................................................................................... 56 
D.2.3.1. Ammonia release assay  .................................................................................. 56 
D.2.3.2. Protease activity assay  .................................................................................... 57 
D.3. Conclusions and perspectives  ............................................................................... 60 
 
E. References  .................................................................................................................. 63 
 
Part II 
Manuscript in preparation: Mónica Uruburu, Eloise Mastrangelo, Martino Bolognesi, 
Giovanni Bertoni, Mario Milani. Crystal structure of the periplasmic domain of TgpA from 
Pseudomonas aeruginosa: structural bases for enzyme activity. 
 
Part III  
F. Prelimiary results ...................................................................................................... 117 
F.1. TgpA in silico docking  .............................................................................................. 117 
  
  
 
 
 
Abstract 
1 
 
A. Abstract 
 
The opportunistic pathogen Pseudomonas aeruginosa is a common agent of infectious 
disease in immunocompromised individuals, and a dominant pathogen in late-stage of cystic 
fibrosis disease. P. aeruginosa represents a prototype of multidrug resistant “superbug” due 
to intrinsic and acquired resistance to antimicrobials agents, for which effective therapeutic 
options are very limited. In order to overcome the current resistance mechanisms, the 
identification and characterization of new cellular functions that are essential for P. 
aeruginosa viability could drive the development of new antibacterial compounds with novel 
mechanisms of action. 
 
The present PhD thesis is focused on the functional and structural characterization of the 
Transglutaminase protein A, TgpA, an inner membrane protein predicted to belong to the 
Transglutaminase-like family which contains a functional TG domain (TG180–544), localized 
in the periplasmic side, suggested to take part in an essential function involved in envelope 
structure. The protein was recently described as essential for the viability of P. aeruginosa, 
and a promising candidate for the design of new specific antimicrobial compounds.  
 
In Part I, the state of the art and main results are presented. First, the in vivo evaluation of 
the modulation of TgpA expression levels on the P. aeruginosa growth showed that, the 
increase of TgpA cellular levels dramatically affects the P. aeruginosa growth. On the other 
hand, the partial suppression of the chromosomal copy of the tgpA gene showed to 
compromised the envelope organization of the cells.  
 
The subsequent structural characterization of the functional TG domain allowed confirming 
that TgpA belongs to the poorly characterized Transglutaminase-like family, in which many 
of the prokaryotic members are proteases. Also, the presence of a carbohydrate-binding 
domain at the N-terminal portion of the protein, suggests that the binding to polysaccharides 
present in the cell wall might constitute a mechanism of regulation of the enzymatic activity 
of TgpA. Moreover, the active site of the protein shares homology with cysteine proteases 
and endopeptidases with described action in the maintenance/biosinthesys of the bacterial 
peptidoglycan, suggesting that TgpA might be involved in the cell wall metabolism. The 
transglutaminase and proteolytic activity of the TG domain were evaluated in vitro, showing 
residual activity over generic substrates.  
Abstract 
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A manuscript in preparation, presented in Part II, describes in detail the characteristics found 
in the structure of the TG domain that are the foundations for the TgpA enzymatic activity.  
 
Finally, in the search for possible inhibitory molecules of the activity of TgpA, the results of 
a preliminary in silico docking analysis with in vivo results are presented in Part III. 
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B. State of the Art 
 
B.1. Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a rod-shaped gram negative and ubiquitous environmental 
bacterium. It belongs to the genus Pseudomonas that contains more than 120 species which 
are all-over in moist environments such as water and soil ecosystems and are infective to 
plants, animals and humans (Spiers et al., 2000; Peix et al., 2009).  
P. aeruginosa is metabolically versatile and has been isolated from numerous nutrient-poor 
settings to the extent that it is able to survive even in distilled water.  Its optimal temperature 
for growth is 37°C. However, it is able to tolerate temperatures as high as 50°C and is 
capable of growing under both aerobic and anaerobic conditions, using preferentially nitrate 
as a terminal electron acceptor (Schreiber et al., 2007).  
In humans, P. aeruginosa is an opportunistic pathogen, capable of acute, severe, invasive 
disease and persistent infections (eluding immune defences) (Kerr and Snelling, 2009). 
Serious infections are often in hospitalized patients, and nearly all associated with 
immunocompromised hosts such as in neutropenia, severe burns, urinary tract infections, 
AIDS, lung cancer, chronic obstructive pulmonary disease and cystic fibrosis (CF) (Driscoll 
et al., 2007, Gellatly and Hancock, 2013). Infections caused by P. aeruginosa are not only 
common but also have been associated with high morbidity and mortality when compared 
with other bacterial pathogens (Harbarth et al., 2002; Osmon et al., 2004). 
 
 
 
Figure B1. Scanning electron microscopy images of P. aeruginosa isolates attaching to glass surfaces. 
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The success of P. aeruginosa as an opportunistic pathogen is due to the versatility and 
adaptability encoded in its relatively large genome (> 6 Mbp), arranged in a core genome 
with a set of conserved regions (90%) interspaced by regions of high plasticity, containing 
genes that are found in only a few strains (Mathee et al., 2008; Silby et al., 2011; Gellatly 
and Hancock, 2013). In the pathogenic strain PAO1, the 10% of its genome encodes for 
regulatory proteins, many of them belonging to the two-component class of regulatory 
system, which allows the bacterium to rapidly adapt to environmental changes, and some 
others implicated in virulence and antibiotic resistance (Gellatly and Hancock, 2013). 
 
B.1.1. Clinical importance  
P. aeruginosa is largely associated with nosocomial infections, even reported as a worldwide 
healthcare issue (Rosenthal et al., 2016).  This pathogen is a prominent cause of health-
care acquired pneumonia and ventilator-associated pneumonia, central line-associated 
bloodstream infection, urinary catheter-related infection and surgical/transplantation 
infections (Report from NNIS System, 2004; Nathwani et al., 2014; Trubiano and Padiglione, 
2015). Mortality rates can be significant (ranging from 7% to 62%), depending on host 
factors (pre-existing comorbidities, including alterations to normal physical barriers of the 
lung, and the presence of immunosuppression and bacterial factors, such as antimicrobial 
resistance and presence of virulence factors (Moore et al., 2016). 
 
In presence of pre-existing lung pathologies, such as certain chronic pulmonary diseases, 
the colonization with P. aeruginosa is very common. In patients with CF, the cause is 
multifactorial, but includes aberrant inflammatory responses, increased pathogen adhesion 
to the endothelium and altered host response to biofilm (Smith et al., 2006; Hogardt and 
Heesemann, 2010; Moradali, 2017).  P. aeruginosa will adapt to CF airways and persist as 
overwhelming, predominant and ineradicable infections to the end of patient’s life in almost 
70% of adults (Döring et al., 2000). 
 
The ability of P. aeruginosa to form biofilms extends to abiotic material and is a key virulence 
factor; colonization of and subsequent infection around prosthetic devices is a frequent 
complication. This ranges from intravascular device-associated bacteraemia (cannulae and 
central lines; particularly in critical care and among immunocompromised patients, such as 
those undergoing chemotherapy or dialysis), to prosthetic joint infections, through to in-
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dwelling intrathecal or intracranial devices in neurology and neurosurgical patients 
associated with CNS infections (Smith et al., 2006; Moore et al., 2016). 
 
Infection with P. aeruginosa can be also a serious complication of burns. In these patients 
the disruption of the tegument, combined with the local immunosuppression that comes with 
burnt tissue (where there is reduced T-cell activity, inflammatory cytokines and 
complement), the colonization frequently progresses to infection (Hogardt and Heesemann, 
2010; Moore et al., 2016). 
 
The predilection of P. aeruginosa for moist areas means wounds, including foot wounds 
among patients with diabetes, which are frequently colonized with this organism and swab 
results commonly report its presence. However, the contribution of this organism to wound 
infections here is less clear; while P. aeruginosa has the potential to cause wound infections 
(including calcaneal osteomyelitis in diabetic foot infections), non-pathological colonization 
is more commonplace (Sadikot et al., 2005; Kipnis et al., 2006; Moore et al., 2016). 
 7 
 
B.2. Pathogenesis and virulence factors of P. aeruginosa 
The pathogenesis of P. aeruginosa has been extensively studied and proven to be a 
multifactorial process mediated by quorum sensing (QS) (Sun et al., 2016). This is a 
mechanism of communication between individual cells facilitated by specific chemical 
signals, called autoinducers (AIs), which are diffused through the membranes, and allows 
for a coordinated adaptation of a bacterial population to environmental changes. QS controls 
the behaviour of bacteria by multiple interconnected signalling pathways (LaSarre and 
Federle, 2013). The number of AIs molecules in the medium is proportional to the 
concentration of bacteria so, when a critical number of bacteria (i.e. “quorum”) is reached, 
the concentration of AIs triggers the activation of specified downstream genes which affects 
the entire bacterial population (Vasil, 2003). More than 10% of P. aeruginosa genes are 
regulated by QS. These genes are mainly involved in virulence factor production, motility, 
motility-sessility switch and biofilm development (Venturi, 2006; Williams and Camara, 2009; 
Barr et al., 2015). 
 
During pathogenesis P. aeruginosa QS plays a critical role for survival and colonization by 
coordinating phenotypic alterations at early stages of infection i.e., after attachment 
(González and Keshavan, 2006). Production of virulence factors is a survival strategy for 
pathogens to evade host immune defence resulting in progression of pathogenesis 
particularly at early stage of colonization or acute infection. QS upregulates the expression 
of genes involved in the production of some destructive virulence factors such as proteases 
(elastase, alkaline protease), pyocyanin, toxins (exotoxin A), rhamnolipids and hydrogen 
cyanide (Jaffar-Bandjee et al., 1995; Lee and Zhang, 2015). Production of these toxic 
compounds is destructive to the host cells/tissues by impairing permeability barrier and by 
inhibiting protein production promoting cell death. Various modes of motility such as 
swimming and swarming involving flagella and twitching using type IV pili are associated 
with virulent traits in P. aeruginosa (Windstanley et al., 2016). A motile cell is readily 
detectable by the host immune system via flagellar and other motility component mediating 
recognition and induction of signalling pathways that trigger inflammatory responses and 
phagocytosis (Amiel et al., 2010). 
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The progress from acute to chronic infection is critically influenced by QS-dependent gene 
expression. Transition from motility to sessile lifestyle requires dynamic regulatory networks 
at transcriptional, post-transcriptional and post-translational levels resulting in coordinated 
timely expression of hundreds of genes. These events mainly arrest flagella based motility 
and the production of virulence factors such as exotoxins and proteases while positively 
regulating surface attachment, extracellular polymeric substances (EPS) production and 
biofilm maturation. The switching is a survival advantage by pathogenic bacteria like P. 
aeruginosa to evade stress and adverse conditions. They lose motility and attach to surfaces 
and form cellular aggregations embedded in EPS to protect bacteria from surroundings 
environment (Leid, 2009; Olsen, 2015). These structures, called biofilm, are characteristic 
of chronic infections and indicative of disease progression and long-term persistence 
(McDaniel et al., 2015). The biofilm creates a niche in which bacteria establish intense cell-
cell interaction and communication as well as a reservoir of metabolic substances, nutrients 
and energy (Flemming and Wingender, 2010). The exopolysaccharides and alginate are 
major constituents of the P. aeruginosa biofilm matrix involved in surface adhesion and 
together with extracellular DNA (eDNA) determine the biofilm architecture. These EPS play 
an important role in resistance to immune responses and antibiotic treatments (Ghafoor et 
al., 2011; Gellatly and Hancock, 2013; Strempel et al., 2013). 
 
Genes involved in the progress of biofilm maturation and persistence are positively regulated 
by QS in P. aeruginosa. The rhamnolipids have been suggested to play an active role in the 
maintenance of the biofilm architecture by contributing to the formation of internal cavities 
allowing proper flow of water and nutrients (Davey et al., 2003; Boles et al., 2005; Dusane 
et al., 2010; Chrzanowski et al., 2012). Additionally, the production of polysaccharide 
(Jennings et al., 2015), eDNA and QS-controlled production of pyocyanine (Das et al., 2013, 
2015) are critical for biofilm maturation. Such molecular and cellular interactions in 
combination with other polymeric substances lead to establishment of a robust and mature 
biofilm. 
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Figure B2. Model of establishment of P. aeruginosa infection. In (a) P. aeruginosa is equipped with a full 
arsenal of virulence traits including pili, flagella, type 3 secretion systems (T3SS) and secreted virulence 
factors. Toxin elaboration injures the surrounding host tissue. The significance of cytosolic invasion during 
human infections is not clear, but breach of the epithelial surface occurs after cell death from toxin injury. 
Epithelial injury also results in loss of mechanical clearance mechanisms and establishment of the 
pseudomonal biofilm leading to a persistent infection. In (b) P. aeruginosa infects an already inflamed surface 
with a defective muco ciliary elevator. The infecting organism mayor may not be piliated, and may already exist 
in a ‘biofilm’ state if acquired from another patient. The infection occurs strictly in the mucous layer where 
‘nests’ of pseudomonads bind to cell debris and extracellular DNA rather than the epithelial surface. The 
pseudomonal micro-colonies are a strong inflammatory stimulus, but are resistant to the actions of neutrophils, 
which may injure surrounding tissue in their efforts to remove the stimulus. Neutrophil death may provide more 
substrate for pseudomonal growth. (Image source Williams, J. Dehnbostel, Sblackwell 2010. Pseudomonas 
aeruginosa: host defence in lung desease, Respirology). 
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B.3. Antibiotic resistance in P. aeruginosa 
P. aeruginosa is intrinsically resistant to many antimicrobials, and capable of developing 
resistance to many others under the influence of previous antibacterial exposure. The 
emergence of antibiotic resistant bacteria is a global health issue, strongly associated with 
nosocomial infections, and a worldwide concern due to increasing development of Multidrug 
Resistant strains (MDR) (Streeter and Katouli, 2016). 
 
B.3.1. Intrinsic resistance mechanisms 
Like many gram-negatives bacteria, P. aeruginosa is intrinsically resistant to many β-
lactams, macrolides, tetracyclines, cotrimazole and most fluoro-quinolones. Such intrinsic 
resistance mechanisms are derived from the presence of genes that encode inherent 
properties of cell structures and composition, providing protection against toxic molecules 
and antimicrobials (Lambert et al., 2011; Blair et al., 2015; Figure B3). 
 
Some hydrophilic antibiotics, such as the broad-spectrum drugs carbapenems and 
cephalosporines, can enter the cell by diffusion through porin proteins in a non-specific 
manner. However, P. aeruginosa limits the antibiotic entry by reducing the expression of 
non-specific porins and replacing them with selective proteins for taking up required 
nutrients, resulting in the lowered permeability to toxic chemicals (Tamber and Hancock, 
2003). 
 
Another mechanism in P. aeruginosa that contributes to antibiotic resistance is based on 
the active multidrug efflux pumps, multi-protein complexes spanning the cell wall. They are 
responsible for the expelling of toxic materials and wide range of antimicrobials. However, 
they are substrate specific, so they show resistance against different classes of chemically 
unrelated antibiotics (Blair et al., 2015, Venter et al., 2015). 
 
In P. aeruginosa, four active multidrug efflux pumps have been described: 
 
1. MexAB-OprM 
2. MexXY-OprM(OprA) 
3. MexCD-OprJ 
4. MexEF-OprN 
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MexAB-OprM and MexXY-OprM(OprA), are the most important, because their large 
prevalence in clinical strains. MexAB-OprM is stable and constitutively expressed in cells, 
guaranteeing a protective basal level that expels consistently a wide range of toxic 
molecules (Li et al., 2015); therefore, it contributes to natural resistance to antibiotics. On 
the other hand, mexXY-(oprA) is mainly induced in response to protein inhibitors that target 
the ribosomal machinery (Matsuo et al., 2004; Hay et al., 2013). Both MexCD-OprJ and 
MexEF-OprN are not expressed in wild-type strains or are slightly expressed, and have been 
proposed not to contribute significantly to natural antimicrobial resistance (Llanes et al., 
2011; Li et al., 2015). 
 
P. aeruginosa produces β-lactamases: enzymes that hydrolyze the peptide bond of the β-
lactam ring leading to their inactivation (Majiduddin et al., 2002). This pathogen is able to 
produce various β-lactamases, including extended-spectrum β-lactamases (ESBL), metallo-
β-lactamases (MBL) and chromosomal cephalosporinase (AmpC) (Oliver et al., 2015). 
AmpC differs from the other β-lactamases because the ampC gene is present in all strains 
of P. aeruginosa, although it requires a gene mutation to cause hyper production and 
antibiotic resistance (Juan et al., 2005). However, through adaptive or acquired resistance 
mechanisms AmpC can be overproduced, consequently conferring resistance to a wider 
range of antibiotics such as aminoglycosides and fluoroquinolones (Umadevi et al., 2011). 
 
 
B.3.2.Mechanisms of acquired resistance  
P. aeruginosa can acquire resistance to antimicrobials through mutations of intrinsic genes 
or by horizontal acquisition of plasmids carrying genetic material encoding for antibiotic 
resistance (Davies, 1997; Davies and Davies, 2010). This type of resistance occurs in the 
presence of antibiotic compounds leading to irreversible resistance population transmittable 
to the progeny (Lee et al., 2016). Mutations in regulatory pathways can increase the 
promoter activities resulting in unleashing gene expression and overproduction of proteins, 
even in genes that confer intrinsic resistance, such as AmpC or multi-drug efflux pumps that 
are regulated by regulatory pathways, causing higher level of resistance (Blair et al., 2015). 
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A clinically important and prevalent mutational alteration is attributed to OprD porin, a 
carbapenem-specific channel localized in the outer membrane of P. aeruginosa. Altered 
OprD reduces the permeability of the outer membrane, leading to the resistance to 
imipenem and reduced susceptibility to meropenem (Epp et al., 2001; Gutiérrez et al., 2007; 
Kao et al., 2016). 
 
Mutational changes within the fluoroquinolone targets i.e., DNA gyrase (gyrA and gyrB) 
and/or topoisomerase IV (parC and parE) or overproduction of active or inducible efflux 
pumps (Lee et al., 2005; Sun et al., 2014; Figure B3) explain the resistance to this kind of 
antibiotics in P. aeruginosa. 
 
Also plasmids are potent vehicles for acquiring resistance genes against different kind of 
antibiotics in P. aeruginosa (Poole, 2011). Transferable plasmids carrying resistance genes 
can be mobile among a wide range of unrelated bacteria, increasing treatment complications 
(Hong et al., 2015). So far, P. aeruginosa resistance via horizontal gene transfer has been 
reported for the genes encoding β-lactam-hydrolyzing enzymes known as the extended-
spectrum β-lactamases and the carbapenemases, aminoglycoside-modifying enzymes, 16S 
rRNA methylases resulting in high-level pan-aminoglycoside resistance (Poole, 2011). 
Genes encoding extended-spectrum β-lactamases and carbapenems, are important not 
only for their hydrolysing activity on a wide range of β-lactam but also for their worldwide 
prevalence (Paterson and Bonomo, 2005; Blair et al., 2015; Sullivan et al., 2015). 
 
Recent findings reported the first evidence of plasmid-mediated colistin (or polymyxin E) 
resistance (Liu et al., 2016). Members of the polymixin family have been the last resort for 
antibiotic treatment of carbapenem-resistant bacteria such as P. aeruginosa isolates 
(Falagas and Kasiakou, 2005). Resistance to polymyxins was previously reported to occur 
via chromosomal mutations (Moskowitz et al., 2012; Gutu et al., 2013), however, new 
evidence suggests plasmid-mediated resistance through the mobilization of the mcr-1 gene, 
first described in Escherichia coli strain SHP45 (Liu et al., 2016). 
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B.3.3. Adaptive resistance mechanisms 
The adaptive resistance mechanism in P. aeruginosa is not very well understood yet, 
however it is known as an unstable and transient form of resistance, induced in the presence 
of specific antibiotics or environmental stress, and reversible upon removal of the external 
stimuli leading to a re-gaining of susceptibility (Barclay et al., 1992; Xiong et al., 1996; 
Fernández et al., 2011). This mechanism has been seen mediating the resistance of P. 
aeruginosa isolates to β-lactams, aminoglycosides, polymyxins and fluoroquinolones 
(Zhang et al., 2001; Poole, 2005; Fernández et al., 2010; Khaledi et al., 2016). 
 
Some P. aeruginosa isolates from CF patients, showed adaptive resistance to 
fluoroquinolones due to multiple mutations in known-resistance genes like nfxB, leading to 
a loss of function of the NfxB transcriptional repressor that regulates the expression of the 
MexCD-OprJ efflux pump. The consequent overproduction of MexCD-OprJ reduces the 
susceptibility to this kind of antibiotics (Wong et al., 2012). Through adaptive mechanisms, 
P. aeruginosa can also acquire and lose resistance to aminoglycosides, polymyxins and 
cationic antimicrobial peptides, by altering the lipid A structure of the LPS (Barrow and Kwon, 
2009; Fernandez et al 2012). Other forms of multidrug efflux pumps such as MexJK, 
MexGHI-OpmD, MexVW, MexPQ-OpmE, MexMN, and TriABC, are not expressed in wild-
type strains but may contribute to adaptive resistance against antibiotic or biocide agents 
when expressed in resistant strains (Lister et al., 2009; Avrain et al., 2013). 
 
The Figure B3 summarizes the different mechanisms of antibiotic resistance in P. 
aeruginosa. 
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Figure B3. Intrinsic, acquired and adaptive mechanisms confer antibiotic resistance in P. aeruginosa. For each 
mechanism, various molecular strategies,which confer resistance to specific class of antipseudomonal 
antibiotics (Car., Carbapenems; Ceph., Cephalosporins; Pen., Penicillins; Ami., Aminoglycosides; 
Flu.,Fluoroquinolones; Mac., Macrolides and Pol., Polymyxins), were presented at the top of the figure 
(underlined) Intrinsic mechanisms such as structural barriers [e.g.,EPS (extracellular polymeric substances)], 
OprD reduction and basal production of AmpC b-lactamase and MexAB/XY efflux pumps confer a basal 
resistance to somegroup of antibiotics. However, in acquired resistance, mutational changes in the oprD gene, 
transcriptional repressors causingupregulation of resistance genes andefflux pumps conferring resistance 
against a wider spectrum of antibiotics. Plasmid-mediated resistance is very potent as a variety of resistance 
genes can beexchanged among bacteria. Either mediated by mutational changes in the genome or in 
plasmids, resistance to polymyxins occurs via modification of LPS (lipopolysaccharide) components hindering 
binding of the antibiotic to this layer. Adaptive resistance occurs in the presence of antibiotics mainly via 
mutation inregulatory genes. This is a transient and reversible resistance, which will reverse upon removal of 
antibiotics. Stars represent antibiotics and dashed/wavy linesrepresent transcriptional levels of each gene 
product. CM, cytoplasmic membrane; OM, outer membrane (Image source Moradali MF, Ghods S and Rhem 
BHA. 2017. Pseudomonas aeruginosa lifestyle: A paradigm for adaptation, survival and persistence. Front Cell 
Infect Microbiol. 7:39 doi: 10.3389/fcimb.2017.00039). 
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B.4. Multidrug resistance in P. aeruginosa 
Resistance development in many human pathogens has taken place on an unprecedented 
scale, as resistance has evolved into multidrug resistance (MDR), leading to increased 
global morbidity and mortality (WHO, 2014). A MDR bacterium is defined as non-susceptible 
to at least one antimicrobial agent in three or more antimicrobial classes, while strains that 
are non-susceptible to all antimicrobials are classified as extreme drug-resistant strains 
(Kallen and Srinivasan, 2010). Bacterial strains belonging to the so-called “ESKAPE” group 
of pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter, P. aeruginosa and Enterobacter) are of importance to this pandemic (Rice, 
2008). These pathogens, both gram-positive and gram-negative bacteria, often carry MDR 
determining genes residing on genetic resistance islands of complex evolutionary origin that 
are encoded on the chromosome or plasmids (Toleman and Walsh 2011; Ellington et al., 
2015; Schmitz et al., 1999). MDR gram-negative bacteria are by far the most important and 
costly in our society today, as they cause the vast majority of nosocomial infections 
(Livermore, 2012), being P. aeruginosa one of the most challenging superbugs (Boyle et al., 
2012). 
 
 
 
Figure B4. P. aeruginosa percentage of invasive isolates with combined resistance (to three or more 
antimicrobial groups among piperacillin + tazobactan, ceftazidime, fluoroquinilones, aminoglycosides and 
carbapenems) by country, EU/EEA countries, 2016. (Image source Antimicrobial Resistance Surveillance in 
Europe 2016 (http://www.ecdc.europa.eu)) 
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According to the Antimicrobial Resistance Surveillance in Europe of 2016 
(http://www.ecdc.europa.eu) high percentages of resistance in P. aeruginosa isolates were 
reported, with almost all the countries showing percentages above 10% for all antimicrobial 
groups under surveillance. Of special concern, 33.9% of the P. aeruginosa isolates reported 
in 2016 were resistant to at least one of the antimicrobial groups under regular surveillance 
(piperacillin ± tazobactam, fluoroquinolones, ceftazidime, aminoglycosides and 
carbapenems). The highest resistance percentage in 2016 was reported for piperacillin ± 
tazobactam (16.3%), followed by fluoroquinolones (15%), carbapenems (15%), ceftazidime 
(13%) and aminoglycosides (10%). Resistance for ceftazidime increased significantly 
between 2013 and 2016, while significantly decreases for fluoroquinolones, 
aminoglycosides and carbapenem resistance were reported during the same period of time.  
More specific analysis indicates that 4.9% of the isolates were resistant to at least three 
antimicrobial groups and 4.4% were resistant to all five antimicrobial classes (piperacillin, 
ceftazidime, fluoroquinolones, aminoglycosides and carbapenems) under the regular 
EARS-Net surveillance.  
 
Carbapenems resistance has led to the introduction of peptides antibiotics, colistin 
(polymyxin E) and polymyxin B, rarely used due to their unattractive toxicity profile, but now 
utilized as last option antibiotics against MDR gram-negative infections that are resistant to 
all other antibiotics (Falagas and Kasiakou, 2005). However, currently little is known about 
their optimal dosing, pharmacokinetics and pharmacodynamics (Boucher et al., 2009). A 
global survey of indications and regimens has found enormous inconsistencies in how and 
when colistin is used, including ways that are clearly suboptimal and could promote 
resistance to it and other polymixins (Wertheim et al., 2013). In fact, resistance to polymyxins 
by P. aeruginosa strains that are normally susceptible to these drugs has been reported 
(Johansen et al., 2008). 
 
Development of novel antimicrobials against P. aeruginosa is therefore of the highest 
importance. At the beginning of 2017 a report made by the World Health Organization 
(WHO), about “Antibiotic-resistant priority pathogens list”, named the bacteria for which new 
antibiotics are urgently needed. International experts from the WHO and the University of 
Tübingen in Germany have identified them according to the level of resistance to excising 
treatment, mortality rates, prevalence in the community and burden on the health system. 
To convey the level of urgency, three priorities for research and development (R&D) were 
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settled: critical, high or medium. The critical priority category includes, in order, multi-
resistant Acinetobacter baumannii, P. aeruginosa and Enterobacteriaceae.  
 
The list is intended to spur governments to put in place policies that incentivize basic science 
and advanced R&D by both publicly funded agencies and the private sector investing in new 
antibiotic discovery. It will provide guidance to new R&D initiatives such as the WHO/Drugs 
for Neglected Diseases initiative (DNDi) Global Antibiotic R&D Partnership that is engaging 
in not-for-profit development of new antibiotics (WHO, 2017). 
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B.5. The crucial role of antibiotics 
The discovery of penicillin in 1928 by Alexander Fleming, led devastating infectious diseases 
previously untreatable, such as streptococcal and chlamydia, suddenly to become treatable 
diseases. Without any doubt, the discovery of antibiotics sparked a new era in the treatment 
of infectious diseases and paved the way for modern medicine. Antibiotic treatment is the 
foundation for surgeries, cancer treatments and treatment of chronic diseases like diabetes 
and cystic fibrosis. Without efficacious antimicrobials, clinical medicine, as known today 
could be jeopardized (Lobanovska and Pilla, 2017). 
 
During the “Golden era” of antibiotics drug discovery from 1940 to 1960, there was a huge 
expansion in the arsenal against bacterial infections through the continue discovery of new 
compounds, by two parallel and independent lines of discovery: 
 
- Identification of small-molecule natural products with an observed antibacterial 
activity: penicillins and cephalosporins, the glycopeptides like vancomycin, and the 
aminoglycosides (Clardy et al., 2009). 
- Discovery of “man-made” molecules with antibiotic activity, such as aromatic sulfa 
scaffolds, originally from the chemical dyes industry or the fluoroquinolones 
(Blondeau, 2004). 
 
During this relative short time period in history, most of today´s known classes of antibiotics 
were discovered (figure B5). From the 1960s to the 1970s, the rise of antibiotic resistance, 
especially in the hospital environment, led to a frantic search for new active compounds, but 
unfortunately screening programs mostly rediscovered existing antibiotics (Lewis, 2013). 
So, pharmaceutical companies developed new antibiotics by improving the already existing 
ones through chemical modifications, tailoring on the periphery of the major antibiotic 
classes, while leaving the core intact (Bérdy, 2005). However, resistance against the new 
versions of old-fashioned antibiotics quickly arise (Figure B5, bottom).  
 
Simultaneously, the lack of success from natural compound screening led companies to 
redirect their efforts to small-molecule chemical libraries, obtaining, also in this case, a very 
poor return of new antibacterial agents. Thus, the development of brand new molecules with 
antibiotic effects must be a priority in microbiological research. 
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Figure B5. Top: Timeline showing the "Golden age” of antibiotic discovery (1940-1960) and “Golden age” of 
antibiotic medicinal chemistry (from 1960 to present). No new structural classes of antibiotics were introduced 
between 1962 and 2000, representing a serious innovation gap during the genomic era. Bottom: first time 
resistance to the class of antibiotics was observed in the clinical setting (Observation of resistance is not equal 
to loss of clinical efficacy against all clinical isolates. Not all classes or antibiotics are included). (Image source 
ClatworthyAE, Pierson E, Hung DT.2007.Targeting virulence: a new paradigm forantimicrobial therapy. Nat 
Chem biol; 3 (9):541-8). 
 
 
 
B.5.1. Classic Antibiotic targets 
Interestingly, most of the known antibiotics inhibit a relatively small number of vital cellular 
functions: I) cell wall synthesis inhibitors, II) protein synthesis inhibitors, III) Inhibition of DNA 
replication or RNA transcription, IV) Inhibition of Folic acid synthesis and V) Membrane 
disruption (Figure B6) (Lewis, 2013).  
 
β-lactam antibiotics (Penicillins, cephalosporins, carbapenems and monobactams) 
represent the most important cell wall inhibitors, targeting the conserved penicillin binding 
proteins (PBPs). PBPs are involved in cross-linking of peptidoglycan precursor Lipid II in 
peptidoglycan synthesis (Typas et al., 2012). Other inhibitors of cell wall synthesis include 
the glycopeptide antibiotic vancomycin that inhibits peptidoglycan synthesis through a 
different mechanism than β-lactams. Their applications result in changes to cell shape and 
size, induce cellular stress responses, and culminate in cell lysis (Tomasz, 1979; Barclay et 
al., 1996). 
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A second category comprises the inhibition of DNA replication, most notably targeting DNA 
topoisomerase complexes by the synthetic quinolone class of antimicrobials, including the 
clinically relevant fluoroquinolone. These molecules interfere with the maintenance of 
chromosomal topology by hitting DNA gyrase and topoisomerase IV, trapping these 
enzymes at the DNA cleavage stage and preventing strand rejoining (Drlica et al., 2008). 
The inhibition of RNA synthesis is due to the action of the Rifamycin class of semi-synthetic 
bactericidal antibiotics. These drugs inhibit DNA-dependent transcription by stable binding, 
with high affinity, to the subunit encoded by the rpoB gene and blocking RNA polymerase 
enzyme (Floss and Yu, 2005). 
 
Protein synthesis inhibitors target either the 30S (aminoglycosides and tetracycline) or the 
50S subunit (macrolides, chloramphenicol and clindamycin) of the 70S ribosome. Most of 
the antibiotics that inhibit the protein synthesis act on the elongation of the polypeptide 
synthesis (Wilson, 2013).  
 
The last category of antimicrobials targets the folate biosynthetic pathway, responsible for 
the de novo synthesis of thymidine and other key cellular components. Folate analogues 
and sulfa derivate drugs, mostly used in combination, block two sequential steps in that 
biosynthetic pathway (Lange et al., 2007). 
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Figure B6. Overview of the cellular targets of most antibiotics, targeting either Gram-negative or Gram-positive 
bacteria. (A) The β-lactams (Penicillin’s, cephalosporin’s, carbapenem`s and monobactam`s) and 
glycopeptide`s inhibit cell wall synthesis; (B) Protein synthesis inhibitors include Aminoglycosides, 
tetracycline’s, macrolides, chloramphenicol’s and clindamycin, which interact with ribosomal subunits 30S and 
50S; (C) Quinolones and fluoroquinolones inhibit the DNA gyrase and topoisomerase IV, Rifamycins 
(Rifampicin) inhibit DNA-dependent RNA polymerase; (D) Sulphonamides and Trimethoprim inhibit folic acid 
synthesis. Not all antibiotic drug classes are represented here. (Image sourceWalsh CT & Wencewicz TA. 
2014. Prospects for new antibiotics: a molecule: entered perspective.J Antibiot 67, 7-22)  
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B.6. The urgent need for new antimicrobials  
Nowadays the widespread antibiotic resistance is considered an important threat to modern 
medicine. In United States it is estimated that more than 2 million people acquire 
antimicrobial resistance infections every year, resulting in approximately 23.000 deaths 
(Fernandez, 2006). In Europe, drug resistant bacteria kill 25.000 people per year 
(Laxminaryan, 2014). The future global impact of antimicrobial resistance has the potential 
to be devastating.  
 
The vast majority of current antibiotics target the same cellular processes as their natural or 
synthetic predecessors (Aminov, 2010). As described before, the range of these targets is 
limited to the components of translational machinery, cell wall biosynthesis, DNA/RNA 
metabolism and some other cellular processes.  
 
It may seem obvious that efforts to develop new antibiotics with novel mechanism of action 
should be a priority. However, the development of new classes of antibiotics has lagged far 
behind the growing need for such drugs. A major factor contributing to the dwindling 
antibiotic pipeline is the decreasing number of companies within the pharmaceutical sector 
that continue to pursue the development of novel antimicrobials (Cooper and Shlaes, 2011), 
due to its decreasing profitability compared to other clinical indications that require longer 
term therapy. It is explicable also because the route to find new antibiotics and develop them 
into drugs is long and expensive. It costs around 1 billion dollars to bring a new drug to the 
market, and it takes on average over of 10 years for it to enter the clinic phase (Lobanovska 
and Pilla, 2017) (Figure B7). 
 
 
 
Figure B7.  Antibiotic drug discovery and development flow chart. (Image sourceWalsh CT & Wencewicz TA. 
2014. Prospects for new antibiotics: a molecule: entered perspective.J Antibiot 67, 7-22) 
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Despite the growing concern of clinicians about the very limited number of therapeutic 
options to mitigate the growing threat of antimicrobial resistance (AMR), a very small number 
of new drugs are currently in late stage of pre-clinical or clinical development (WHO 2017). 
A total of 51 antibiotics are in the clinical pipeline, but only eight of these belong to new 
antibiotic classes and have been classed as innovative by the WHO. Among them, 
Murepavidin, is the only one that showed specific activity against P. aeruginosa (including 
resistant strains) (De Winter et al., 2017) and is a synthetic macrocyclic protegrin mimetic 
that inhibits the lipopolysaccharide-assembly protein (Giuliani and Rinaldi, 2011; Botos et 
al., 2017) and has now completed phase-2 studies (NCT02096315, NCT02096328). 
 
In this scenario, there is an impelling need for the identification of novel drug targets and the 
discovery of new-generation of antibiotics. Notably, the recent discovery of new promising 
antimicrobials with a completely new mechanism of action (Freire-Moran et al., 2011; Ling 
et al., 2015) indicates that we have only explored a fraction of the microbial targets that 
could be used for antibiotic drug discovery.  
 
A rational development of antibacterial drugs with novel mechanisms of action requires the 
identification of new molecular targets that may emerge from a better understanding of 
cellular processes essential for cell survival and/or pathogenicity. In this view, large-scale 
systematic analysis of gene essentiality represented an important step towards the 
characterization of novel potential drug targets (Fernandez-Piñar et al., 2015). 
 
 
 
 
B.6.1. Novel essential genes as antimicrobial targets  
In order to avoid being compromised by any of the current resistance mechanisms, it is 
desirable to develop compounds acting against unexploited targets (Tomaši and Peterlin. 
2014). Over the last two decades the availability of genome sequencing techniques and 
transciptomics and proteomics approaches that permit the global characterization of 
bacterial components, have raised the possibility that antibiotic discovery can be performed 
by first identifying high value bacterial targets, like genes required for its growth and survival 
(Juhas et al., 2012), and then developing compounds that inhibit these targets.  
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Although the genome sequences of approximately 2700 bacteria have already been 
released in public databases (Pagani et al., 2012; Huang et al., 2014), a number of crucial 
cellular pathways, such as secretion, cell division, and many other metabolic functions, 
remain uncharacterized and untargeted up to today (Kohanski et al., 2010; WHO 2017). 
 
It seems logical to assume that bacterial components necessary for growth and survival 
would serve as ideal targets for the identification of inhibitory compounds that demonstrate 
antibacterial activity. An essential gene is defined as one whose loss is lethal under a certain 
environmental condition (Xu et al., 2011) but, regarding laboratory conditions where this 
essentiality is assessed, it typically refers to the ability to grow on solid media and form a 
colony in different experimental requirements (Fang et al., 2005). So, the identification of 
essential genes plays a primary role not only in the research of potential targets for 
antimicrobial drug development but also in unravelling the minimal gene set for living 
organisms (Koonin, 2003; Gil et al., 2004; Glass et al., 2006) and deciphering bacterial 
relationships during evolution (Liao et al., 2006; Koonin, 2009). 
 
Furthermore, although important, many processes and pathways are not ubiquitous and, in 
most cases, are only shared by a subset of bacterial strains that are not well characterized 
(Jordan et al., 2002). It is therefore evident that understanding and modelling the complexity 
of a living organism require global elucidation of gene function as well as the identification 
of the essential genes (de Berardinis et al., 2008).  
 
 
 
B.6.2. P. aeruginosa essential genes as antimicrobial targets 
Recent analysis through different approaches, such as transposon mutagenesis, Tn-seq 
and Shotgun antisense, led to the identification of a number of general and condition-specific 
P. aeruginosa essential genes (Boutros and Ahringer, 2008; Christen et al., 2011; de 
Berardinis et al., 2008; French et al., 2008; Gallagher et al., 2011; Juhas et al., 2012b; 
Langridge et al., 2009; Lee et al., 2015; McCutcheon and Moran, 2010; Moule et al., 2014; 
Moya et al., 2009; Rusmini et al., 2014; Sigurdsson et al., 2012; Skurnik et al., 2013; Turner 
et al., 2015). 
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A number of these genes are not essential in mammals cells therefore are considered as 
candidate drug target. That is the case for the genes implicated in asparagine-tRNA 
biosynthesis (Lee et al., 2015). But more important, there are essential genes that have 
been described indispensable for P. aeruginosa but not for other bacteria, and are 
considered to be good targets for P. aeruginosa specific antibiotics. These include genes 
involves in the central carbon energy metabolism and protection from reactive oxygen 
species (Lee et al., 2015), genes that are required for P. aeruginosa growth under clinically 
relevant conditions, such as cystic fibrosis sputum and genes necessary for pathogenesis 
(Turner et al., 2015). 
 
Recently, new antibiotics with novel mechanism of action support the idea that essential 
bacterial genes may be high valuable targets for the development of antimicrobials. The 
identification and characterization of inhibitors of the LpxC enzyme, a zinc-dependent 
deacetylase that catalyzes the first committed step in lipid A biosynthesis in gram negative 
bacteria (Barb et al., 2008; Tomaras et al., 2014) is one good example. LpxC inhibitors have 
shown potent in vitro activity against the multidrug resistant gram negative species Klebsiella 
pneumoniae, Escherichia coli and P. aeruginosa (Brown et al., 2012; Montgomery et al., 
2012). Another successful example of an essential gene in P. aeruginosa targeted by an 
antimicrobial with novel mechanism of action is the recently developed peptidomimetic 
compound that targets the β-barrel of the outer membrane protein LptD, an essential gene 
for biogenesis of the cell envelope. In complex with the lipoprotein LptE, LptD transports 
LPS from the periplasm to the outer membrane (Wu et al., 2005; Srinivas et al., 2010; 
Wernebur et al., 2012).  
 
 26 
 
B.7. Transglutaminase Protein A –TgpA, a novel essential 
protein in P. aeruginosa 
 
In P. aeruginosa was recently described a set of novel essential genes through Shotgun 
antisense RNA libraries (SALs). In this approach, essential genes are identified after 
shotgun-cloned genomic fragments and DNA sequencing of the growth-impairing fragments 
identifies those genes targeted by antisense RNA (Rusmini et al., 2014). 
 
The essentiality of a novel candidate, locus PA2873, encoding for Transglutaminase Protein 
A or TgpA, was further explored using different approaches such as insertional mutagenesis 
and conditional mutagenesis, demonstrating that the gene product TgpA, is indeed essential 
for the viability P. aeruginosa (Figure B8) (Milani et al., 2012). 
 
 
 
 
 
Figure B8. Mutagenesis analysis of locus PA2873 - tgpA gene. (A) Insertional mutagenesis on each indicated 
locus targeted for knock-out by homologous recombination-mediated cointegration of the suicide vector pDM4 
carrying chloramphenicol resistance (CmR). The dnaG gene for DNA primase and the algR gene for a LytTR-
type two-component response regulator were used respectively as positive and negative controls of 
essentiality. (B) Conditional mutagenesis. The rhamnose inducible/glucose repressible promoter PrhaB was 
inserted upstream to tgpA giving rise to PAO1 PrhaB::tgpA strain. Specificity of glucose/rhamnose effects on 
the growth of PAO1 PrhaB::tgpA was assessed by monitoring the PAO1 cultures in M9-citrate supplemented 
with either rhamnose or glucose. Note the opposite effects of glucose on growth of PAO1 PrhaB::tgpA and 
PAO1, respectively.(Image source Milani A, Vecchietti D, Rusmini R, Bertoni G. 2012. TgpA, a protein with a 
eukaryotic-like transglutaminase domain, plays a critical role in the viability of Pseudomonas aerugnosa. PloS 
One, 7(11): e50323 doi: 10.1371/journal.pone.0050323). 
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TgpA is a medium size inner membrane protein (668 amino acids, 75 KDa) (Vecchietti et 
al., 2012) composed of six-seven transmembrane helices, a soluble periplasmic domain 
containing the functional domain (residues 180-544, 364 aa) and followed by an additional 
transmembrane helix and a small cytoplasmic domain (residues 561-668) (Figure B9). 
 
The periplasmic portion of TgpA was predicted to display a eukaryotic-like transglutaminase 
domain (TG-like domain) (Makarova et al., 1999) with unknown function, characterized by 
the presence of a conserved catalytic triad Cys, His, and Asp. It was suggested that TgpA 
can take part in an essential function linked to the cell wall, such as i) assembly of 
peptidoglycan structures ii) maturation/secretion of key periplasmic proteins iii) assembly of 
surface polypeptide structures, or iv) biogenesis/maturation of LPS. 
 
 
 
 
Figure B9. TgpA location and organization in the inner membrane of P. aeruginosa. The region TG180–544 
that contain the functional TG domain have a high probability of being exposed on the outward face of 
cytoplasmic membrane, i.e. to protrude into the periplasmic space.  
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B.7.1. Transglutaminases  
Transglutaminases (TG: EC 2.3.2.13, protein glutamine: amine γ-glutamyltransferase) are 
a group of thiol enzymes that catalyse the post-translational modification of proteins mainly 
by protein to protein cross-linking, but also through the covalent conjugation of polyamines, 
lipid esterification, or the deamidation of glutamine residues (Folk and Chung, 1973; Lorand 
and Conrad, 1984; Aeschlimann and Paulsson, 1994; Nemes et al., 1999).  
 
Transglutaminases catalyze the calcium-dependent acyl-transfer reaction between a γ-
carboxyamide group of glutamine and ε-amino group of lysine or other primary amines, 
which results in the formation of γ-glutamyl-ε-lysine peptide chains bridges (Lorand and 
Conrad, 1984). These enzymes thus establish either intramolecular or intermolecular cross-
links in proteins. Transglutaminases are widely distributed among bacteria, plants and 
animals.  
 
In general, TG employs a charge-relay Cys-His-Asp catalytic triad with the reaction involving 
formation of a covalent acyl-enzyme intermediate (Figure B10). During the reaction, (step 
1) the thiolate ion nucleophilically attacks the Gln side chain (the acyl donor or Q substrate), 
leading to the formation of an oxyanion intermediate (step 2). Then, the regeneration of the 
carbonyl group of the tetrahedral intermediate leads to the release of ammonia and to the 
formation of the acyl−enzyme intermediate (Step 3); the catalytic His removes a proton from 
the primary amine of the Lys residue (Step 4), leading to the nucleophilic attack of the Lys 
residue on the carbonyl group of the acyl−enzyme intermediate formed in step 3 and to the 
formation of a second tetrahedral intermediate (Step 5). As the oxyanion intermediate 
regenerates the carbonyl group, the thioester bond is cleaved, regenerating the initial 
catalytic core and releasing the final, cross-linked, protein product (Step 6) (Fernandez et 
al., 2015). 
 
Interestingly, this reaction is the reversion of the proteolysis reaction catalysed by the thiol 
proteases that possess the same catalytic triad (Anantharama and Aravind, 2003). 
 
  
29 
 
 
 
Figure B10. Proposed reaction mechanism of the animal TG on the basis of the similarity of their catalytic core 
to that of papain-like proteases (Image source Fernandez CG, Placido D, Lousa D, Brito JA, et al. 2015. 
Structural and Functional Characterization of an Ancient Bacterial Transglutaminase Sheds Light on the 
Minimal Requirements for Protein Cross-Linking. Biochem 54(37):5723-34doi: 
10.1021/acs.biochem.5b00661) 
 
 
The solved crystal structure of the human blood-clotting factor XIII (Yee et al., 1994), a 
mammalian transglutaminase, allowed clarifying that transglutaminases and papain-like 
proteases shared core structural fold, and are classified into the same superfamily in the 
Structural of Proteins (SCOP) database (Hubbard et al., 1999). It is suggested that, the 
catalytic core of TG derive from the minimal ancestral structural unit of the thiol-protease 
fold (Anantharaman and Aravind, 2003). 
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B.7.2. Transglutaminases-like superfamily of enzymes  
Computational analysis allowed the identification of a superfamily of proteins, found in all 
archaea, bacteria, yeast and nematodes, that are homologous to eukaryotic 
transglutaminases. This family of large multidomain archeal proteins with predicted signal 
peptide and a globular domain (TG domain) that contains conserved cysteine, histidine and 
aspartate, which compose the catalytic core in the structurally characterized 
transglutaminase, human blood clotting factor XIIIa (Makarova et al., 1999), which is also a 
reminiscent of the catalytic triad of a variety of thiol hydrolases (Anantharaman and Aravind 
2003). The discovery of this superfamily suggests an evolutionary scenario for the origin of 
eukaryotic transglutaminases from ancient proteases.  
 
In the sequenced euryarchaeal genomes at least one protein of the transglutaminase-like 
superfamily was found (Makarova et al., 1999). The vast majority of these proteins have not 
been functionally characterized, but it has been predicted that many of the prokaryotic 
members are proteases, although it cannot be ruled out that some of them actually possess 
a transglutaminase activity. The presence of multiple transglutaminase homologs in 
Mycobacteria implies a possible role for these proteins in the development of the unusual 
surface structures found on them (Brennan and Nikaido, 1995). Some others have been 
functionally characterized with specific but non-essential functions at cell wall level. In the 
Methanothermobacter species, prophage proteins PeiW and PeiP act as pseudomurein 
endoisopeptidases (Steenbakkers et al., 2006; Visweswaran et al., 2010; Schofiel et al., 
2015). In the periplasm of Bordetella bronchiseptica, WbmE protein catalyzes the 
deamidation of uronamide-rich O chains of lipopolysaccharide (LPS) (King et al., 2009). 
 
B.7.3. Prokaryotic proteins with similar TG domain  
B.7.3.1. Pseudomurein endoisopeptidases PeiW and PeiP 
Pseudomurein is a kind of cell wall polymers present in Archaea, found only in 
Methanobacteriales and the genus Methanopyrus (Kurr et al., 1991; Kandler and König, 
1993; Kandler, 1993; Albers and Meyer, 2011). Structurally, is similar to the murein, 
predominant component of the bacterial cell wall, but differs for the presence of an archaeal-
specific sugar, N-acetyltalosaminuronic acid in the glycan bond (instead of the bacterial N-
acetylmuramic acid) linked by β(1-3) bonds to N-acetylglucosamine or N-
acetylgalactosamine. The lack of D-amino acids in the peptide chain and the use of ε- and 
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γ-iso-peptide bond in both the peptide and interpeptidyl cross-link, are also important 
features that make the different between these two molecules (Hartmann and König, 1990; 
König et al., 1993; Kandler and König, 1998). 
 
 
 
Figure B11. Composition of pseudomurein and murein cell walls. G:N-acetylglucosamine; T:N-
acetyltalosaminuronic acid; M:N-acetylmuramic acid. Methanogen pseudomurein contains L-amino acids, 𝛽 
(1-3) bonds, and N-acetyltalosaminuronic acid in the glycan chain and several unusual isopeptide bonds. Asp 
can replace Glu; Thr or Ser can replace Ala, in some strains. Bacterial murein contains D- and L-amino acids 
and 𝛽 (1-4) bonds and N-acetylmuramic acid in the glycan chain. (Image source Schofield LR, Beattie AK, 
Tootill CM, Dey D, et al., 2015. Biochemical characterization of phage Pseudomurein endoisopeptidases PeiW 
and PeiP using synthetic peptides. Archaea 2015:828693 doi 10.1155/2015/828693). 
 
 
Pseudomurein endoisopeptidases (Pei), PeiW and PeiP, are two lytic enzymes that degrade 
the pseudomurein cell wall sacculi (Luo et al., 2002). PeiW is encoded by the defective 
prophage ΨM100 of the thermophile Methanothermobacter wolfei (Luo et al., 2001), and 
PeiP is encoded by phage ΨM1 and deletion mutant ΨM2 of the thermophile 
Methanothermobacter marburgensis (Stax et al., 1992; Pfister et al., 1998).  
 
These two enzymes share the same catalytic triad of conserved cysteine, histidine and 
aspartate residues, as the transglutaminases and thiol proteases, located at the C-terminus 
of each enzyme. The N-terminus consists of a pseudomurein cell wall binding domain 
containing four pseudomurein-binding motifs (Visweswaran et al., 2010; Steenbakkers et 
al., 2006). Both enzymes causes lysis of the cell wall because they cleave the isopeptide 
bonds formed between the ε-amino group of an L-lysine residue and the α-carbonyl group 
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of an L-alanine residue in the oligopeptides linking sugar chains of pseudomurein (Kiener et 
al., 1987). For this activity they require a divalent metal and have been shown enhanced 
thermal stability in presence of Ca2+ (Schofiel et al., 2015). 
 
 B.7.3.2. WbmE of Bordetella bronchiseptica 
The lipopolysaccharide (LPS) O antigen of the human pathogen Bordetella bronchiseptica 
contains a homopolymer of 2,3-dideoxy-2,3-diaceramido-L-galacturonic acid (L-
GalNAc3NAcA), that can also be found in the uronamide form (L-GalNAc3NAcAN) (Di Fabio 
et al., 2009). The expression of O antigen is required for full virulence in animal models of 
infection and for resistance to complement-mediated killing (Preston et al., 2006).  
In B. bronchiseptica the O antigen synthesis is encoded by the wbm locus that contains 24 
coding sequences. The WbmE, a periplasmic deamidase protein, catalyzes the conversion 
of a proportion of deamidation of uronamide-rich O chains in LPS (L-GalNAc3NAcAN) to L-
GalNAc3NAcA uronic acids. WbmE is a member of the papain-like transglutaminase 
superfamily, with conserved residues Cys-His-Asp, consistent as well with the deamidation 
role (King et al., 2009). This enzyme probably constitutes a novel mechanism by which the 
B. bronchiseptica cell surface is modified in response to environmental stimuli. 
 
B.7.3.3. AdmF, transglutaminase involved in the synthesis of Andrimid 
AdmF is a protein expressed from a gene cluster related with the biosynthesis of Andrimid, 
a potent promising antibiotic with activity over unconventional targets such as the β-subunit 
of the acetyl-CoA carboxylase (ACC) (Needham et al., 1994; Singh et al., 1997; Freiberg et 
al., 2004; Freiberg et al., 2005). 
 
The biosynthesis of this natural product is widely distributed in bacteria and involves a highly 
dissociated hybrid PKS/NRPS assembly line, with each carrier protein located on a separate 
subunit. Interesting features of this unusual pathway include the catalysis of peptide bond 
formation by transglutaminase-like enzymes, executed by AmdF (Fortin et al., 2007), a 
protein that contains the complete Cys-His-Asp catalytic triad characteristic of TG and that 
has shown the capacity to combine characteristics such as amide bond formation and 
involvement of an acyl-enzyme intermediate. In vitro biochemical assays with purified 
recombinant protein AdmF have demonstrated a broad substrate tolerance (Magarvey et 
al., 2008). 
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B.8. Bacterial cell wall and peptidoglycan structure 
The cell wall is of vital importance for bacteria because it determines the shape and the 
integrity of the cell, by surrounding the cytoplasmic membrane with a net-like macromolecule 
called peptidoglycan (PGN, or murein) sacculus (Weidel and Pelzer, 1964; Vollmer et al., 
2008a). The essential PGN is made of glycan chains cross-linked by short peptides, and is 
located in the periplasm of gram-negative bacteria as a thick monolayer or multi-layered wall 
in gram-positive species (Schleifer and Kandler, 1972; Vollmer and Bertsche, 2008b; 
Vollmer and Seligman, 2010). 
 
The glycan strands are made of alternating N-acetylglucosamine (GlcNAc) and N-
acetylmuramid acid (MurNAc) residues, linked by β-1,4 glycosidic bonds [GlcNAc-(β-1,4)- 
MurNAc], and having a pentapeptide, containing L- and D-aminoacids,  attached to the D-
lactyl moiety of each MurNAc.  The pentapeptide sequence varies across bacteria species 
and can be L-Ala-D-γ-Glu-m-Dap-D-Ala-D-Ala (m-Dap, meso-diaminopimelic acid) in gram 
negatives species or L-Ala-D-γ-Glu-L-Lys-D-Ala-D-Ala in gram-positives, and participates in 
an interglycan cross-linking reaction between peptides of adjacent strands, building the 
three-dimensional PGN network (Schleifer and Kandler, 1972; Vollmer and Bertsche, 
2008b; Vollmer and Seligman, 2010). 
 
 
Figure B12. Peptidoglycan structure. (A) The polysaccharide backbone of peptidoglycan is linked by stem 
peptides. Gram-negative bacteria and Gram-positive Bacilli contain meso-diaminopimelic acid (m-DAP) as the 
third amino acid in the peptide linker. (B) Most other Gram-positive bacteria (including Gram-positive cocci) 
contain l-lysine as the third amino acid in the linker. GlcNAc, N-acetylglucosamine; MurNAc, N-acetylmuramic 
acid. (Image source Brown L, Wolf JM, Prados-Rosales R and Casadevall A. 2015. Through the wall: 
extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi. Nat Rev Microbiol13, 620-630 doi: 
10.1038/nrmicro3480 
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B.8.1. P. aeruginosa peptidoglycan structure 
As gram-negative, the murein sacculus of Pseudomonas consists of the glycan moiety of β-
1,4-linked alternating units of GlcNAc and MurNAc followed by the peptide L-Ala-D-γ-Glu-
m-Dap-D-Ala-D-Ala.  
The glycan reveals only a few variations such as acetylation of phosphorylation of the 
muramyl 6-hydroxyl groups and the occasional absence of a peptide of an N-acetyl 
substituent. In different Pseudomonas species the glycan length varies between 10 and 65 
dissaccharide units in comparison to up to 30 in E. coli and 50-250 in the case of Bacillus 
sp. (Quintela et al., 1995); Margolin 2009; Dimitriev et al., 2005).  
 
The peptide moiety is bound through its N-terminal to the carboxyl group of the MurNAc, 
followed by glutamic acid, which is linked by its γ-carboxyl froup to an L- m-Dap and finally 
D-Ala-D-Ala. Variations in peptidoglycan composition may involve amidation, hydroxylation, 
acetylation, and also the mode of cross-linkage of aminoacids and other groups at position 
2 or 3 of the peptide moiety. These features allow to classify the peptidoglycan in the 
different categories established by Shleifer and Kandler, 1972. According to this, the 
peptidoglycan of P. aeruginosa is of classified as the “not amidated A1γ” chemotype, 
characterized by the lack of amidation at the C1-carboxy group of D-Glu and L-m-Dap, as 
well as the 4-3 cross-link involving the stem peptide by L-m-Dap: the free aminoacid group 
(ω-amino group) of the L-m-Dap in position 3 forms a peptide linkage to the carboxyl group 
of D-Ala in position 4 of an adjacent peptide subunit (Figure B12a).  
 
 
B.8.2. Peptidoglycan synthesis 
The PGN layer has a flexible structure and is constantly remodelled during cell growth and 
division. Growth of the sacculus is a dynamic process that requires more than 20 enzymatic 
reactions (Lovering et al., 2012), including synthases to make PGN and attach it to the 
existing sacculus and hydrolases to cleave the sacculus to allow insertion of the newly 
synthesized material (Höltje, 1998). The PGN synthesis takes place in the cytoplasm 
(synthesis of nucleotide precursors) and on the inner membrane and outer side of the 
cytoplasmic membrane (synthesis of lipid-linked intermediates and polymerization 
reactions) (Vollmer et al., 2008c; Barreteau et al., 2008). 
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In the cytoplasm, the conversion of fructose-6-phosphate to uridine diphosphate-N-acetyl 
glucosamine (UDP-GlcNAc) is taken in a four-step reaction catalysed sequentially by GlmS, 
GlmM and GlmU enzymes. UDP-MurNAc is then formed from UDP-GlcNAc in a reaction 
catalysed by MurA enolpyruvyl transferase and MurB reductase successively. Then MurC, 
MurD, MurE and MurF ligases mediate the assembly of the pentapeptide on the D-lactoyl 
group on UDP-MurNAc, giving rise to the formation of UDP-MurNAc-pentapeptide 
(Barreteau et al., 2008). 
 
On the cytoplasmic face of the inner membrane, MraY catalyzes the reaction of UDP-
MurNAc-pentapeptide with undecaprenyl pyrophosphate to generate MurNac-pentapetide 
pyrophosphoryl undecaprenol or Lipid I, which is then coupled with GlcNAc by the MurG 
transferase to yield GlcNAc (pentapeptide) phosphoryl undecaprenol, also known as Lipid 
II (Bouhss et al., 2008). Then, lipid II is translocate to the outer side of the cytoplasmic 
membrane. Both, MurJ and FtsW, have been proposed to be the lipid II flippase, yet 
remaining a matter of debate (Ruiz, 2008; Mohammadi et al., 2011; Sham et al., 2014). 
Once in the periplasm, lipid II is the disaccharide donor for glycan strand growth, catalyzed 
by the transglycosilase domain of Penicilling Binding Proteins (PBP). Cross-linking of the 
peptide stems occurs in a separate transpeptidase reaction, also mediated by PBP (Fisher 
et al., 2005).  
 
The transpeptidation is generally considered the last step in the PGN synthesis, but the 
structure of the cell wall suffers constant remodeling and modifications: for instance, O-
acetylation is a mechanism against PGN-cleaving lysozymes and regulates glycan strand 
integrity against lytic transglycosilases cleavage (Moynihan and Clarke, 2011). Also the 
peptide stem undergoes important modifications. D-Ala-D-Ala carboxypeptidases remove 
the terminal D-Ala from the pentapeptide stem, in order to regulate the degree of final cross-
linking, generating a tetrapeptide no longer suitable as a substrate for cross-linking by D-
Ala-D-Ala transpeptidases (Zhang et al., 2007; Shi et al., 2008; Sauvage et al., 2008).  
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B.8.3. Peptidoglycan turnover and recycling 
As mentioned before, during growth and division the cell must keep its integrity. Initially, it 
was thought that the peptidoglycan grew with progressive elongation. However, it was later 
described a process in which both, growth of sidewalls and new septum of the bacteria, 
coincided with the release of the existing PGN as the incorporation of the new PGN occurred 
(Höltje, 1998; Park and Uehara, 2008). The process was described as a dynamic recycling 
of the released PGN, both in gram-negative and in gram-positive bacteria, but is yet less 
characterized in the last system (Reith and Mayer, 2011). 
 
Briefly, the PGN turnover – the release of muropeptides to the medium – occurs through the 
simultaneous action of different PGN hydrolases, located in the periplasm and cytoplasm of 
the bacteria (Typas et al., 2011). Lytic transglicosylases (LTs) are critical for the recycling of 
cell wall during growth (elongosome) and cellular division process (septation), and catalyze 
the cleavage of the glycan strand of the PGN, with the formation of N-acetyl 1,6-
anhydromuramic acid. The LTs can cleave at the end of the glycan strand (exolytic LT) or 
in the middle of the PGN chain (endolytic LT). 
 
The main reaction product is the N-acetyl-β-D-glucosamine-(1-4)-1,6-anhydro-N-acetyl-β-
D-muramyl-peptide (NAG-anhNAM-peptide), which is internalized to the cytoplasm by 
AmpG permease. NagZ, a cytoplasmatic glucosaminidase, further hydrolyzes the glycosidic 
bond between NAG and anhNAM-peptide, and then AmpD (PGN amidase), releases the 
peptide stem from the anhNAM sugar. These products are then reincorporated to the PGN 
biosynthetic pathway (Fisher and Mobashery, 2014; Dominguez-Gil et al., 2016).  
 
The complexity of the events that occurrs in the cytosol, inner membrane, periplasm and 
outer membrane of the gram-negative bacteria related to the PGN synthesis, turnover and 
recycling are illustrated in Figure B13 from Fisher and Mobashery 2014. 
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Figure B13. Events in the synthesis, turnover and recycling of PGN in Gram-negative bacteria. (Image source 
Fisher JF and Mobashery S. 2014.The sentinel role of peptidoglycan recycling in the β-lactam resistance of 
the Gram-negative enterobacteriaceae and Pseudomonas aeruginosa.Bioorg Chem 56:41-8 doi 
10.1016/j.bioorg.2014.05.011) 
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C. Aim of the work 
The characterization of new cellular functions that are essential for P. aeruginosa viability 
could drive the development of new antimicrobial compounds with novel mechanisms of 
action.  
 
Therefore, during this PhD work the main aim was to gain knowledge about the crucial role 
played by the transglutaminase protein A, or TgpA, in the viability of Pseudomonas 
aeruginosa, and increase the rationale for targeting the activity as a novel approach to 
identify new antibacterial drugs.  
 
To achive this goal, initially it was evaluated the impact of mutations that were predicted to 
knock down the TgpA activity on the growth of P. aeruginosa; and then, through the 
expression and purification of recombinant domains of TgpA, focusing on the periplasmic 
TG domain responsible for the catalytic activity of the enzyme, to characterize the protein at 
structural and biochemical level.  
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D. Main results  
D.1. Evaluation of the impact of mutations predicted to knock-down TgpA activity on 
the growth of P. aeruginosa in different genetic systems 
 
The first step of the analysis, aimed to evaluate whether ectopic expression of the wild type 
(wt) full-length TgpA protein and some variants with mutations in the predicted catalytic triad, 
could per se influence the growth of P. aeruginosa in the wt background of the PAO1 strain. 
Therefore, the wt tgpA gene (PA2873) was amplified from PAO1 genomic DNA and cloned 
into the broad host range expression vector pHERD28T (Qiu et al., 2008) under the control 
of the arabinose-inducible PBAD promoter. Mutations in the predicted catalytic triad Cys404 
– His448 – Asp464, were generated through site-directed mutagenesis (Stratagene Kit) 
using as a template the pHERD28T vector expressing a wt full-length TgpA protein. A point 
mutant of the main residue Cys (Cys404Ala) and a double mutant in residues Cys and His 
(Cys404Ala-His448Asn) of the catalytic triad, were generated, as shown in Figure D1.  
 
 
 
 
Figure D1. Panel of amino acid substitutions in the TG domain catalytic triad Cys404–His448–Asp 464 
 
 
The generated constructs pHERD28T-TgpA and those carrying the respective mutation 
(pHERD28T-C404A and pHERD28T- C404A- H448N) were transferred from E. coli (where 
they were prepared) to P. aeruginosa PAO1 strain by triparental mating conjugation. 
 
To test the hypothesis that unbalancing the tgpA expression could be deleterious for P. 
aeruginosa, the effects of the PBAD promoter modulation on growth rate of PAO1- 
pHERD28T-TgpA and mutants relative to PAO1 carrying an empty vector pHERD28T were 
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assayed. Overnight cultures of PAO1- pHERD28T-TgpA and mutants in M9-citrate 
supplemented with trimethoprim 300 μg/ml were diluted to OD600 = 10-6 and inoculated in 
microtiter wells filled with 200μl of growth medium and five different concentrations of 
Arabinose (0; 0.025; 0.05; 0.1 and 0.2%) for the induction of the PBAD promoter. 
 
 
Figure D2. Effects of the ectopic expression of TgpA WT and mutants C404A and C404A-H448N on P. 
aeruginosa growth. The effects on growth were evaluated relative to PAO1 carrying the empty vector 
pHERD28T under five different concentrations of arabinose (0, 0.025, 0.05, 0.1 and 0.2%) for the induction of 
the PBAD promoter. For each culture, the OD600 value after 16 hrs of growth (i.e. the onset of the stationary 
phase) was plotted with the corresponding concentration of arabinose. 
 
 
The ectopic expression of WT and the two mutants proteins C404A and C404A-H448N 
resulted in an arabinose dose-dependent negative influence on P. aeruginosa growth 
(Figure D2). The overexpression of a wt copy of TgpA and the single mutant C404A leads 
to a decrease in the growth rate of P. aeruginosa, while the overexpression of the double 
mutant C404A-H448N dramatically decreased the growth of the cells, suggesting that an 
extra dosage of TgpA could be deleterious for the bacteria. The negative effects on the P. 
aeruginosa growth resulting from the ectopic expression were specific of TgpA. In fact, the 
ectopic expression from pHERD28T of another essential protein, YeaZ (Vecchietti et al., 
2016), involved in tRNA modifications, did not result in significant negative effect on PAO1 
growth (data not shown). These negative effects were evident and comparable among wt 
and the mutants, also in absence of arabinose (Figure D2). In fact, in this condition the TgpA 
expression was attributed to the basal activity of the PBAD promoter.  
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Next, the levels of ectopic expression of the wt and mutants from pHERD28T, particularly in 
the absence of inducer arabinose were assessed by western blot analysis (Figure D3) and 
quantified it by Real time PCR (Table D1).  
 
For western blot analysis, full-length C-terminal His-tagged constructs were generated using 
as template the wt and C404A already cloned in the pHERD28T vector, with appropriate 
primers adding the His-tag. Cultures with 0.1% arabinose and without arabinose were grown 
and the membrane fractions isolated by subcellular fractionation with ultracentrifugation at 
37,000rpm, were used for the analysis. With a specific monoclonal anti-His antibody a 
unique band around 70 kDa, corresponding to TgpA-His (wt and mutant C404A), was 
detected relative to the absence of the band in the empty vector (Figure D3). The presence 
of a small band also in the absence of the arabinose inducer, both in the wt and the mutant 
C404A, provided evidence of the basal activity of the PBAD promoter. 
 
 
 
Figure D3. Western blot analysis of the ectopic expression of the TgpA wt and C404A full-length proteins in 
absence and presence arabinose. Ten microliters of total membrane fraction from the growth under each 
conditions were loaded onto 12% SDS-PAGE. Samples induced with 0.1% Ara are diluted 1:10 with respect 
to the sample without arabinose. MW = Molecular weight marker 
 
 
The basal activity of the PBAD promoter was further confirmed by Real time quantitative PCR 
(qRT-PCR) reactions. One millilitre from each of the samples produced for the western blot 
analysis was normalized at OD600 0.8 and total RNA was extracted to further generate cDNA. 
Approximately 50ng of cDNA were used as a template for qRT-PCR. The calculation of the 
relative expression of the ectopic TgpA from plasmid pHERD28T versus the empty vector 
was performed as described by the 2-ΔΔCT method (Livak and Schmittgen, 2001), normalizing 
first mRNA amounts to 16S ribosome RNA (ΔCT) and relating the ΔCT in theTgpA wt and 
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C404A mutant ectopically expressed to the chromosomal copy (ΔΔCT) (PAO1-pHERD28T 
empty vector).  
 
In Table D1 are reported the 2-ΔΔCTvalues of the ectopic expression of tgpA mRNAs. These 
values confirmed that in the absence of arabinose inducer, tgpA wt and mutated form are 
ectopically expressed more than ten times respect to the chromosomal copy due to the basal 
activity of the PBAD promoter. 
 
 
Table D1. Quantitative Real time PCR analyses of mRNA levels of ectopically 
overexpressed TgpA wt and C404A mutant 
 
 
Strain 0% Ara 0.1% Ara 
PAO1-pHERD28T 1* 1 
PAO1-pHERD28T-TgpA wt 16 544 
PAO1-pHERD28T-C404A 11 363 
 
*Values represent 2-ΔΔCT values of the ectopic expression of tgpA mRNAs 
 
Following the overexpression experiments in PAO1 background, vectors pHERD28T –TgpA 
wt and mutants C404 and C404A-H448N were transferred from E. coli to the PAO1 
derivative strain PAO1- PrhaB::tgpA (Milani et al., 2012). This strain is a conditional mutant 
carrying a chromosomal copy of the tgpA gene under the control of the PrhaB (rhamnose 
dependent) promoter. This strain is usually maintained in the presence of rhamnose that 
induces the expression of the tgpA from the PrhaB promoter. However the PrhaB promoter can 
be strongly down regulated by glucose addition in the medium. Consequently, PAO1 
PrhaB::tgpA is unable to growth in the presence of glucose unless functional TgpA is 
ectopically expressed from another promoter. 
 
TgpA wt and mutants, ectopically expressed from vectors pHERD28T, were tested for the 
ability to complement a glucose-mediated down-regulation of the chromosomal tgpA gene 
in PAO1 PrhaB::tgpA. As shown in Figure D4, wt tgpA allele expressed from pHERD28T-
TgpA wt by the basal activity of PBAD promoter (Ara 0%) is able to complement the forced 
repression by 1% glucose of the PrhaB promoter. In fact, PAO1 PrhaB::tgpA could grow with 
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1% glucose as much as with the permissive condition of 0.2% rhamnose. Differently from 
TgpA wt, both tgpA mutant alleles expressed from pHERD28T- C404A and pHERD28T- 
C404A-H448N, respectively, by the basal activity of PBAD promoter (Ara 0%) could not 
complement the forced repression by 1% glucose of the PrhaB promoter (Figure D4). 
Therefore, the mutations C404A andC404A-H448N impairs the in vivo functionality of TgpA. 
 
 
 
 
Figure D4. Tests of complementation of a glucose-mediated down-regulation of the chromosomal tgpA gene 
in PAO1 PrhaB::tgpA. PAO1 PrhaB::tgpA strains carrying pHERD28T-TgpA wt (A), pHERD28T- C404A (B) and 
pHERD28T- C404A-H448N (C) were grown for 20 hrs in micro-cultures of 200 µl with the indicated 
concentrations of arabinose, rhamnose and glucose concentrations. Cultures growth was monitored in real-
time by absorbance measurement at OD600.  
 
 
 
 
 
 44 
 
The consequences in reducing the expression levels of TgpA were further investigated by 
Transmission Electron Microscopy - TEM. The conditional strain PAO1 PrhaB::tgpA was 
grown either in the absence or in the presence of a sub-lethal concentration of glucose that, 
although strongly reducing the growth-rate, gave rise to a sufficient amount of P. aeruginosa 
cells for TEM analysis. Figure D5 shows the results of these experiments. 
 
PAO1 PrhaB::tgpA cells with glucose presented two abnormal morphological features:  
1. The average cell length is greater than the reference condition with rhamnose.  
2. The presence of “collapsed-zones” that might originate from the detachment of the inner 
membrane from upper layers of the envelope. 
 
These results are consistent with the hypothesis that TgpA has a role at cell wall level, in 
particular the collapsed-zones visible following TgpA depletion suggests a role in anchoring 
inner membrane to upper layers of the envelope.  
 
 
 
Figure D5. Morphological analysis of P. aeruginosa cells with reduced TgpA levels: I) PAO1 PrhaB::tgpA cells 
grown o/n in M9 medium with rhamnose; II) PAO1 PrhaB::tgpA cells grown o/n in M9 medium with glucose, 
8000X magnification; III) PAO1 PrhaB::tgpA cells grown o/n in M9 medium with glucose, 12000X magnification; 
IV) PAO1 PrhaB::tgpA cells grown o/n in M9 medium with glucose, 16000X magnification. 
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D.2. Structural characterization of the TG domain 
To gain knowledge about the organization and possible aspects of the function of the 
protein, was solved the structure of the soluble periplasmic domain (residues 180-544) 
containing the functional Transglutaminase (TG) domain, characterized by the presence of 
the conserved catalytic triad Cys – His – Asp.  
 
D.2.1. Expression and purification of the TG domain 
The periplasmic portion of TgpA, TG180–544 (364aa), was cloned into the non-commercial 
p2N vector (PRIMM srl.; Ampicillin (Amp) resistance) expressing a N-terminally (His)10-
tagged TG domain. The E. coli strain BL21CodonPlus (DE3) - RIPL was used for the 
expression of the TG domain, with overnight induction with 1 mM isopropyl β-D-
thiogalactopyranoside (IPTG) at 17°C with 220 rpm agitation. The purification of the protein 
was performed by nickel affinity followed by size exclusion chromatography (SEC) (Figure 
D6, panel A and B). The concentrated protein (6 mg/ml) was used to perform crystallization 
trials with microbatch set-up using an Oryx-8 crystallization robot (Douglas Instruments, East 
Garston, UK). TgpA crystals were obtained after 48h at 20°C (Figure D6, panel C).  
 
 
 
 
 
Figure D6. Summary of the purification and crystallization of the TG domain. (A) SEC elution profile of the TG 
domain; (B). SDS-PAGE showing the separation of the two bands of the TG domain during SEC, M) Molecular 
weight marker; the number of each line is representative of the indicated fraction from the SEC elution in panel 
A; (C). TG domain crystals 
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During the TG domain expression and purification, the protein showed the tendency to 
undergo proteolytic cleavage, evident by the presence of two bands around 40kDa (Figure 
D6 Panel B lane 1). Anti-His western blot analysis confirmed that both bands correspond to 
his-tagged proteins, suggesting that TgpA cleavage occurs at the C-terminal end. Such 
feature suggests a disordered nature of this part of the sequence.  
 
For mass spectrometry analysis, both bands were digested with trypsin and other 
peptidases, and the pattern of fragmentation was compared with the overall sequence of 
the protein to identify the cleavage sites. As shown in Figure D7, the Band 1, corresponds 
to the expected molecular weight of the TGdomain (364aa, 44kDa), and the generated 
peptides covers up to seven amino acids before the end of the sequence. On the other hand, 
the Band 2, corresponds to a cleaved version of the TG domain, with fragments generated 
mainly by other peptidases different from trypsin. This truncated version of the protein, of 
approximately 39kDa, presents a region at the C-terminal portion that suffers proteolytic 
cleavage around Tyr499, generating different peptide fragments. Although it was not 
possible to identify a precise site of cleavage, it was possible to confirm that the protein 
loses more than 20 amino acids at its C-terminal end.  
 
 
 
Figure D7. Mass spectrometry analysis of the two bands obtained during the TG domain purification. In Red 
are highlighte all the peptides generated by tripsin digestion and identified with mass analysis. In Green are 
highlithed those peptides generated by digestion with other peptidases different from trypsin 
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D.2.2. Solving the structure of the periplasmic TG domain  
A detailed description and analysis of the structure of the TG domain is found in Part II in 
“manuscript in preparation”.  
 
The native TG domain crystals diffracted to a maximum resolution of 1.6 Å using synchrotron 
radiation at bem-line ID30a3 at the European Synchrotron Radiation Facility (ESRF-
Grenoble, France). However, it was not possible to solve the structure through molecular 
replacement (MR), since TgpA has low homology respect to other proteins with structure 
already solved. In the cases where MR it is not possible, classic methods like heavy-atoms 
derivatization (where the crystals are soaked with heavy-atoms (HA) containing compounds) 
are used to create isomorphous HA derivatives (same unit cell, same orientation of the 
protein in cell). This strategy gave rise to measurable intensity changes that could be used 
to deduce the position of the heavy atoms (Taylor, 2010). 
 
The TG domain crystals were soaked with mercury derivatives and collected data to a 
maximum resolution of 1.8 Å at beam-line BM14U (ESRF-Grenoble, France) (Figure D8).  
 
 
Figure D8. A. Electron density after heavy atom (Hg) phasing B. Superposition between the two TG domain 
structures: Blue native TG domain, grey mercury (Hg) derivative 
 
X-ray diffraction data were indexed and scale using XDS (Kabsch, 2010) and the three-
dimensional structure was solved using the SAD method based on mercury derivative, using 
the package SHELXC/D/E (Sheldrick, 2010) within the CCP4i interface (Potterton et al., 
2003). The obtained experimental electron density was used to trace an initial protein model 
with ARP/WARP (Lamzin and Wilson, 1997). The single TG domain molecule present in the 
crystal asymmetric unit was then subjected to manual (program COOT (Emsley et al., 2010) 
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and constrained refined using REFMAC5 (Steiner et al., 2003), and the model was used for 
molecular replacement to solve the structure of the native dataset (Vagin and Teplyakov, 
1997). Additional refinements with BUSTER (Smart et al., 2012) and REFMAC5 were 
subsequently performed for both datasets.  
 
The experimental electron density of the TG domain allowed modelling all the protein 
sequence between Val195 and Leu482 that is around 17 amino acids upstream respect to 
the cleavage region (Figure D9). The TG domain is folded in a tripartite globular structure 
composed of two sub domains linked by a central antiparallel beta sheet composed of four 
strands. The N-terminal portion of the domain is mainly composed of β strands, with a major 
solvent exposed antiparallel β sheet (made by 6 strands), which could be considered as a 
putative regulatory domain. On the contrary, the C-terminal domain contains the conserved 
catalytic triad and is mainly composed of alpha helices (Figure D9).  
 
 
 
Figure D9. Blue N-terminal portion putative regulatory domain; yellow catalytic triad; red C-terminal catalytic 
domain 
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Structure-based analysis with DALI server (Holm, 2010) allowed identifying homology 
between the TG domain with the eukaryotic transglutaminase coagulation factor XIII (pdb-
id 4kty, Z=6.4, id. 22%). The similarity is restricted to the conserved catalytic core with Cys-
His-Asp residues, and also to the presence of certain residues in its proximities, like the 
presence of a Gly two amino acids upstream of the catalytic Cys and aromatic residues (Trp) 
two amino acids downstream of the catalytic His and also flanking the Asp from the N-
terminal side. This led us to consider that TgpA belongs to the poorly characterized group 
of Transglutaminase-like superfamily of enzymes, typified by the structure of the human 
coagulating factor XIII (Makarova et al., 1999). 
 
 
 
Figure D10. Superimposing catalytic triad of the human transglutaminase coagulation factor XIII (green) with 
TG domain (blue).  
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D.2.2.1. N-terminal portion: A regulatory domain? 
Structural analysis restricted to the N-terminal portion of the protein (from Val195 to Ala323), 
established similarity with different carbohydrate binding domains like the chitin binding 
domain (chitinase, pdb-id 5dhe, Z=2.8, 13% identity (Hanazono et al., 2016)), xylan binding 
domain (xylanase, pdb-id 1xbd, Z=2.7, 7% identity) and sugar binding (GH52 Beta-D-
xylosidase; pdb-id 4rhh, Z=3.4, 7% identity), suggesting that this portion of the protein could 
be involved in the binding of polysaccharides presents in the cell wall and this might 
constitute a mechanism of regulation of the enzymatic activity of TgpA.  
 
The major component of bacterial cell wall is the PGN, a complex polymer formed by long 
glycan chains cross-linked by peptide stems, which requires constant balance between 
synthesis and degradation, by a well-orchestrated set of proteins from different classes. 
Most of these proteins are PGN hydrolases that contains cell wall binding motives that 
recognize specific fragments of the cell wall. Such is the case of the well-characterized 
SPOR (PF05036), LysM (PF01476), SH3b (PF08460), PGN-binding domain type 1 
(PF01471), DUF3393 (PF11873) or WxL (PF13731) domains (Alcorlo et al., 2017). 
However, the mechanisms of PGN recognition and regulatory mechanisms of the enzymes 
involved in its metabolism are still largely unknown. 
 
Considering these arguments, the ability of the TG domain to bind bacterial PGN was 
investigated by a pulldown assay (Wong et al, 2013). In such experiments the protein that 
binds to the PGN will coprecipitate with the ligand and is found in the pellet after 
centrifugation. As shown in Figure D11, in presence of increased concentrations of PGN 
from P. aeruginosa the TG domain localized in the pellet, suggesting interaction between 
the two molecules. In absence of PGN the TG domain remains soluble. The helicase from 
virus dengue was used as a control, showing no detectable binding.  
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Figure D11. Pulldown experiments with insoluble PGN. The binding capacity of the (A) TG domain and (B) 
helicase were assayed by Pulldown assay with increasing concentrations of insoluble PGN from P. aeruginosa. 
The lanes are labelled as follows: MW = Molecular weight marker, P = Pellet, S = Supernatant 
 
 
To further validate the binding capability of the TG domain, the specificity of the interaction 
was assessed through Microscale Thermophoresis – MST. For this purpose, the binding 
capacity of the TG domain was compared towards the sacculi from P. aeruginosa and. B. 
subtilis (Sigma), a gram-positive bacteria with PGN classified as amidated A1γ (L-m-Dap 
amidated). Negative controls of binding were performed with labelled helicase from dengue 
virus under the same conditions used for the TG domain.  
 
Knowing the insoluble nature of the bacterial sacculi, a pilot experiment was carried out 
using the soluble fraction of the sacculi extracted from P. aeruginosa and B. subtilis. After 
centrifuging the mixture, the dry weight of the insoluble fraction of the PGN from B. subtilis 
allowed establishing that the 50% remains soluble (5mg/ml). A standard curve was set with 
the soluble fraction measuring the absorbance at 280nm (A 280nm), and an estimated 
concentration of the soluble fraction of the isolated PGN from P. aeruginosa was 
determined. 
 
With the hypothesis that the binding between the the TG domain and PGN is given by the 
glycans present in each molecule of the muropeptide, the molecular weight of the 
disaccharide GlcNAc-MurNAc (496.466g/mol) was used to calculate a hypothetical 
dissociation constant (Kd). 
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The TG domain – PGN interaction was monitored by titrating PGN form P. aeruginosa from 
0.125 mM to ∼7.6 nm and higher concentration of B. subtilis were used to define better the 
curve, from 5 mM to ∼150 nM. The TG domain and helicase labelled with the Kit RED-NHS 
(NanoTemper technologies, Munich, Germany), were kept at constant concentration 75 nM. 
The changes of the fluorescent thermophoresis signals were plotted and Kd values were 
determined using the NanoTemper analysis software, through non-linear curve fitting.  
 
In this exploratory analysis, it was possible to conclude that the TG domain has the ability 
to bind the PGN, both from P. aeruginosa and B. subtilis (Figure D12). The affinity for both 
type of PGN is in the μM range, however the TG domain shows greater affinity for the PGN 
from P. aeruginosa (Table 2). 
 
The negative control, helicase from dengue virus, does not bind the PGN from P. 
aeruginosa, but it binds to the PGN from B. subtilis with a Kd in the milimolar range, around 
10 times the value of the Kd for the binding of the TG domain and the B. subtilis PGN.  
 
 
 
 
Figure D12. TG domain and PGN binding affinity was analysed by MST. The TG domain – PGN interaction 
was monitored by titrating PGN of (A). PAO1 from 0.125 mM to ∼7.6 nm, and (B). B. subtilis from from 5 mM 
to ∼ 0.1 nM, against 75 nM of TG domain labelled with the Kit RED-NHS (NanoTemper technologies, Munich, 
Germany). The changes of the fluorescent thermophoresis signals were plotted and Kd values were determined 
using the NanoTemper analysis software, through non-inear curve fitting. The change in MST signals was 
fitted to yield the hypothetical Kd. 
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Table D2. Binding constants for PGN ligands. The equilibrium dissociation constants (Kd) 
are given in μM. NS: Not significative 
 
 Kd (μM) 
P. aeruginosa B. subtilis 
TG domain 39± 2 210 ± 4 
helicase NS 1800± 390 
 
 
These results suggest that the TG domain has the ability to bind PGN with greater affinity 
for P. aeruginosa samples. Although the PGN of P. aeruginosa and B. subtilis do not differ 
much structurally, only in the amidation on m-Dap in B. subtilis, it could be suggested that 
this difference was sufficient to establish a difference in binding affinity. However, more 
detailed analyses are required with different purified muropeptides oligomers to establish 
the specificity of the interaction. Likewise, it should be clarify the boundaries of the N-
terminal domain to which PGN is bound and the residues involved in it. 
 
Although it is true that the domain identified at the N-terminal end of the TG domain has no 
homology with the already known domains that bind to the bacterial PGN, the mechanisms 
of recognition of bacterial PGN and regulatory mechanisms of the enzymes involved in its 
metabolism are still largely unknown. 
 54 
 
D.2.2.2. TG domain active site  
A detailed description and analysis of the active site of the TG domain is found in Part II in 
“manuscript in preparation”. 
 
Structural analysis with DALI server restricted to the active site found homology with a 
transglutaminase-like putative cysteine proteases (pdb-id 3ISR, Z=9.8, id. 18%) and a 
putative protease (pdb-id 3KD4, Z=8.7, id. 17%), both from gram-negative bacteria; although 
these enzymes have not been functionally characterized they are classified as hydrolases. 
An additional analysis of the overall geometry of the active site residues using the LabelHash 
server (Moll et al., 2011) found homology with the active site of a Cys endopeptidase acting 
on muropeptides (Xu et al., 2009). Therefore all the structure-based analyses suggest that 
the protein might be somehow involved in the cell wall metabolism. 
 
Interestingly, with the solved structure of the TG domain it was possible to establish that the 
active site Cys404 is buried inside the protein at about 10 Å from the protein surface (Figure 
D13), and that probably it becomes accessible when the right substrate is present. So far, it 
has not been possible to accurately define the specific substrate for the protein, but we 
hypothesized that, in a truncated version of the protein, in which a portion of the C-terminal 
end is removed, the catalytic site will be more exposed and accessible for generic 
substrates, and measurement of protein activity in vitro will be possible.  
 
 
Figure D13. (A) TG domain structure. The C-terminal portion is colored in Red, showing how encloses the 
active site. (B) Cys residue is colored in Yellow 
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For this purpose, two shorter truncated forms of the TG domain were generated, considering 
also the previously described cleavage at the C-terminal end of the protein. One of the 
truncated forms terminates at the amino acid Pro471 (P471) and the other one at the amino 
acid Glu480 (Q480). Both constructs were cloned and expressed in the same manner as 
the wt TG domain (described above), and after affinity purification and size exclusion 
chromatography both proteins were observed as single bands on SDS-PAGE (Figure D14). 
However, both proteins were highly unstable and prone to precipitate. With the addition of 
10% glycerol in the elution buffer the truncated form P471 remained soluble and available 
to be evaluated for activity in vitro. 
 
 
 
Figure D14. Purified recombinant truncated forms of TG domain, P471 and Q480. SDS-PAGE 12% MW = 
Molecular weight marker 
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D.2.3.In vitro activity assays 
D.2.3.1. Ammonia release assay 
Typically, transglutaminases catalyze an acyl-transfer reaction between the γ-carboxamide 
group of a protein- or peptide-bound glutamine and the ε-amino group of a lysine residue, 
releasing ammonia in the process. In the search for a method that would allow the 
measurement of transglutaminase activity of the TG domain for high throughput screening 
(HTS) purposes, a sensitive method has been modified and established for the detection of 
the ammonia released during the formation of acyl intermediates in the transglutaminase 
reaction. The reaction between ammonia and the fluorescent ortho-phthalaldehyde (OPA) 
produces coloured polymeric products that can be used for fluorescent detection and 
quantification.  
 
Thus, the release of ammonia was assessed in a reaction between the TG domain and a 
commercially available substrate used to characterize transglutaminase activity, Z-Gln-Gly 
(Z-QG), which acts as a γ-glutamyl donor during the first step of the TG reaction. A human 
transglutaminase II, TG2, was used as a positive control, setting a standard curve with serial 
dilutions ranging from 200nM to 0.1 nM in reaction. The reaction between each enzyme and 
substrate was kept at 37°C for two hours. The reaction products were detected by the 
addition of OPA and the fluorescence intensity was read on TECAN after 1 additional hour. 
As blank, it was considered all the components of the reaction mixture except for the 
presence of the substrate. The fluorescence reading of the blank sample was substrated 
from the flouorescence value of each tested sample, and the enzymatic activity was 
compared to the standard curve. The substrate was also evaluated to verify that it did not 
contain ammonia contaminants that could affect the fluorescence reading. 
 
As can be seen in the Figure D15, the fluorescence values due to the ammonia release are 
not comparable between the positive control TG2 and the two recombinant forms of the TG 
domain, wt and P471, when incubated with the substrate Z-QG. However, the fluorescence 
values observed with the TG domain and truncated form P471 (around 2000 fluorescent 
units) are not considered trivial; the small amount of ammonia released during the reaction 
may be due to the fact the Z-QG substrate is not specific for the TG domain. This can be 
considered as a residual transglutaminase activity that might be potentiated in the presence 
of the right substrate for the TG domain.  
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Therefore the ammonia release method with the substrate Z-QG is not the method of choice 
to measure the possible transglutaminase activity that the TG domain could have. 
 
 
Figure D15. Ammonia release assay of TG domain. 200nM of purified protein, TG domain and P471, were 
tested for the ammonia release assay. For the positive control Human Transglutaminase 2, TG2, was 
established a standard curve using serial dilutions starting from 200nM to 0.1 nM in reaction. 20mM of the Z-
QG substrate and 4mM of the fluorescent OPA reagent were used. In the figure are plotted the fluorescence 
product of the ammonia release of 200 nM of each protein, TG2, TG domain and P471. One asterisk 
represents p-value 0.03. The results are representative of three independent experiments.  
 
 
D.2.3.2.Protease activity assay 
The conserved catalytic triad Cys-His-Asp, also present in diverse enzyme families such as 
cysteine proteases and peptide N-glycanases (PNGases), which are all members of the 
transglutaminase protein superfamily, suggests that TG domain might have a cysteine 
protease activity.  
 
To determine if the TG domain has cysteine protease activity in vitro, was used a kit 
designed for the detection of protease activity (serine, aspartic, cysteine and 
metalloproteinases) using fluorimetry based on the hydrolysis of casein labelled with 
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fluorescein isothiocyanate (FITC) as general substrate. A standard curve with the positive 
control Trypsin was established with serial dilutions from 2.5μg/ml to 0.15μg/ml in reaction. 
The TG domain and the truncated form P471 were tested at a concentration of 20 μg/ml. 
The proteolytic reaction was performed at 37°C and after 2 hrs was stopped with 
trichloroacetic acid (TCA) and after centrifuged the sample, the processed soluble fragments 
of fluorescent casein were measured. The blank of the proteolytic reaction was carried out 
in the same manner previously described for the ammonia release assay. 
 
Through pulldown assay and MST experiments we demonstrated that TG domain can bind 
PGN from P. aeruginosa, so we speculated that this binding could act as a regulatory 
mechanism of the enzymatic activity and generate conformational changes in the protein, 
exposing and making the catalytic site accessible so that it can fullfils its function. For this 
reason, it was performed the proteolytic reaction in presence of 5μg of PGN from P. 
aeruginosa.  
 
As shown in figure D16, the fluorescence product of the proteolytic activity is not comparable 
between the positive control and the TG domain. The trypsin enzyme used as a positive 
control showed much higher activity on the casein substrate than TG domain in its forms, wt 
and truncated P471. However, it is important to point out that in the presence of PGN from 
PAO1 the proteolytic activity of the truncated form P471 showed a significant increase in 
fluorescence with respect to the TG domain wt, which could be considered as a residual 
proteolytic activity. This suggests conformational changes in the TG domain structure due 
to the presence of PGN that allowed the casein substrate to be partially cleaved. 
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Figure D16. Protease activity on the general substrate FITC casein. 20μg/mlof TG domain and P471 were 
tested for protease activity on the casein FITC substrate, in presence of 5μg/mlof P. aeruginosa PGN. For 
the positive control, a standard curve with trypsin from 2.5μg/ml to 0.15 μg/ml. In the figure are plotted the 
fluorescence product of the proteolytic activity of 0.3 μg/ml of trypsin vs 20 μg/ml of TG domain and P471. 
The truncated form P471 shows residual protease activity on the general substrate casein. Three asterisk 
represents significant difference; p-value < 0.0001.The results are representative of three independent 
experiments. 
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D.3. Conclusions and perspectives  
 
The current rise in multi-drug resistant P. aeruginosa is of particular concern. Nowadays, 
this ubiquitous bacterial pathogen is accepted worldwide as a public health risk due to its 
increasing prevalence in healthcare acquired infections combined with its ability to develop 
resistances to multiple classes of antibiotics. Urgent and novel strategies to discover new 
antibiotics are required and the study of essential genes has proved to be an interesting 
strategy in medicine for the identification of important antimicrobials targets.  
 
This PhD work provides initial insights towards the characterization of TgpA, an essential 
protein for the viability of P. aeruginosa, and a promising target for the design of new specific 
antimicrobial compounds. 
 
From the initial analysis, in which substitutions in the predicted main residues of catalytic 
triad Cys404 and His448were evaluated for their effects on the P. aeruginosa growth, it was 
possible to speculate about the importance of these two residues for the activity of the 
protein. The fact that PAO1 PrhaB::tgpA strain was unable to growth in the presence of 
glucose unless functional TgpA was expressed ectopically from another promoter, 
confirmed the essentiality of the Cys404 and His448 residues for the activity of TgpA.  
 
Regarding phenotypic effects, the results of the partial suppression of the chromosomal 
copy of the tgpA gene were consistent with the hypothesis that TgpA has an important role 
at the cell wall level; in particular the visible “collapsed-zones” following TgpA depletion 
suggest a possible role of anchoring inner membrane to upper layers of the envelope, or in 
the assembly of peptidoglycan structures. These results are also in agreement with the TgpA 
overexpression that could affect the envelope dynamic and thus leads to the growth 
impairment.  
 
Metabolomic or proteomic profiles of the periplasm of P. aeruginosa with the PAO1 
PrhaB::tgpA strain could help to clarify the essential role that the protein plays for the viability 
of the cell. As well as the identification of possible natural substrates for the evaluation of 
the enzymatic activity.  
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On the other hand, the solved structure of the periplasmic TG domain showed the presence 
of two subdomains: The N-terminal, a possible regulatory domain linked to different 
carbohydrate binding domains, and the C-terminal hosting the conserved catalytic triad 
Cys404-His448-Asp464 involved in a specific enzymatic activity.  
 
The exploratory analysis on the interaction between the TG domain and peptidoglycan 
resulted in directing the hypothesis about the regulatory role of the N-terminal subdomain 
and showing some hints on how the mechanism of ligand binding and activation of the C-
terminal catalytic subdomain may occur in order to carry out its function. The binding 
between TG domain and peptidoglycan was found to be quite specific (in the μM range) 
when compared to the ability of the dengue virus helicase to bind to the same ligand. At the 
same time, the residual proteolytic activity observed with the generic substrate casein, when 
the reaction is conducted in presence of the peptidoglycan, suggest a mechanism of 
conformational changes in the TG domain structure when is bounded to the peptidoglycan 
that allows the exposure the catalytic site and this one can fullfil its function.  
 
These results are yet preliminary and future studies are required to assess whether the 
binding to the peptidoglycan is at the N-terminal subdomain and also to describe the key 
residues involved in the binding. Also, the question remains open on what is the portion of 
the peptidoglycan to which the protein binds. Additional exploratory studies about the 
binding capacity of other molecules present in the cell wall (e.g. LPS) should be carried out 
to identify other possible protein substrates. 
 
Evidences collected in this work show some key points that can direct the evaluation of the 
protein activity in vitro, which remains one of the priorities for future studies and for high 
throughput screening purposes. In particular, it seems interesting to analyse the importance 
of the presence of aromatic residues around the active site and how this are related with the 
activity of the protein. These residues could be also crucial for the inhibition of the activity, 
for which in silico docking studies are continuing.  
 
Furthermore, it could be interesting to explore the importance of a C-terminal domain that is 
predicted to be cytoplasmic and that is found after the last transmembrane domain (residues 
582-638 belonging to the DUF4129 superfamily) of the TgpA full-length protein. Preliminary 
analyses through bioinformatics tools, allow identifying that this domain is not characterized 
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yet, but is closely related to transglutaminases proteins. It could be a domain that facilitates 
the union of a cytoplasmic substrate / cofactor important for the regulation / function of the 
protein. Currently the C-terminal cytoplasmic domain is in the process of purification. 
 
In conclusion, our results expanded the knowledge about the essentiality of TgpA for the 
viability of P. aeruginosa, providing initial evidence regarding the characterization of the 
protein at molecular, cellular, structural and biochemical level, valuable for the future design 
of novel antimicrobials acting specifically on P. aeruginosa.  
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ABSTRACT  
 Pseudomonas aeruginosa is an opportunistic pathogen associated with 
severe diseases, such as like cystic fibrosis. During an extensive search for novel 
essential genes, we identified the gene tgpA (locus PA2873) in P. aeruginosa 
PAO1, which plays a critical role in the bacterial viability. TgpA is an internal 
membrane protein with a periplasmic soluble domain predicted to be endowed 
with a transglutaminase-like fold with a Cys, His, and Asp ‘catalytic triad’. We 
present here that the Cys residue in such triad is required for the essential function 
of TgpA relative to P. aeruginosa viability.and the crystal structure of the TgpA 
soluble domain as a first step towards structure-activity analysis of a new target 
for the discovery of novel antibacterial compounds. 
 
1. Introduction 
Infections caused by resistant gram-negative bacteria are becoming 
increasingly prevalent, and a serious threat to public health worldwide, being 
associated with high morbidity and mortality rates. Colonization with resistant 
gram-negative bacteria is common among residents in long-term care facilities, 
particularly for patients with an indwelling device, causing serious concern in 
hospitals. 
Pseudomonas aeruginosa is a gram-negative opportunistic pathogen 
responsible for many diseases such as chronic lung colonization in cystic fibrosis 
patients and acute infections in hospitals (Driscoll et al., 2007). P. aeruginosa 
infections are always difficult to treat due to the natural resistance of this 
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bacterium (Obritsch et al., 2005), consequently a therapy based on two or three 
antimicrobial agents is typically adopted (Lodise et al., 2007) (Szaff et al., 1983) 
(Valerius et al., 1991). Unraveling novel essential genes or pathways that have 
not yet been targeted by clinical antibiotics can foster the development of new 
effective antibacterials to overcome resistance. We recently discovered an 
essential gene for P. aeruginosa viability coding for the protein TgpA (Milani et al., 
2012). TgpA is a medium size inner membrane protein (668 amino acids) 
composed of five transmembrane helices, a periplasmic domain (residues 180-
544) followed by an additional transmembrane helix, and a small cytoplasmic 
domain (residues 561-668). The periplasmic portion of TgpA was predicted to 
host an eukaryotic-like transglutaminase domain (TG-like domain) (Makarova et 
al., 1999) of unknown function, characterized by the presence of a Cys, His, and 
Asp ‘catalytic triad’ .  
In this work, we demonstrate that the Cys residue in such triad is required 
for the essential function of TgpA relative to P. aeruginosa viability. 
Furthermore, we present here the crystal structure of the TgpA periplasmic 
domain, solved using SAD methods after soaking the crystal with a mercury 
compound. The periplasmic domain is composed of two sub-domains, one 
hosting the catalytic triad of the predicted TG-like domain, and the other 
structurally linked to different carbohydrate binding domains that may play a role 
in substrate recognition. 
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2. Materials and Methods 
 
2.1 Construction of plasmids expressing His-tagged TgpA wt and the 
mutant C404A in the full-length protein  
A plasmid expressing a His-tagged full length TgpA was prepared by 
amplifying the tgpA gene (locus PA2873) from P. aeruginosa PAO1 genomic DNA 
with primers 5’-TATCATGAACGCGATTCCGCGGGTC-3’ and 5’-
AGAAGCTTGTAAAGCTTTCAGTGGTGGTGGTGGTGGTGTGCCTGCTCCTCT
C-3’. Amplicons were digested with BspHI and HindIII restriction enzymes and 
cloned into the broad host range vector pHERD28T (Qiu et al, 2008), digested 
with NcoI and HindIII, under the arabinose inducible promoter PBAD, giving rise to 
the plasmid pHERD28T-TgpA.  
The QuikChange II XL Kit (Stratagene) was used to generate the mutant 
Cys404Ala, using as a template the construct pHERD28T-TgpA, with the 
complementary primers carrying the mutated codon 5’- 
GCGCAGCGGCTTCGCCGCGCATTACGCC-3’ and 5’-
GGCGTAATGCGCGGCGAAGCCGCTGCGC-3’.  
For overexpression, the constructs pHERD28T-TgpA-His and pHERD28T-
C404A-His were moved from E. coli JM109 to PAO1 strain by triparental mating 
as described previously (Milani et al., 2012). PAO1 cells carrying pHERD28T-
TgpA-His, pHERD28T-TgpA-C404A-His, or the pHERD28T empty vector were 
grown for 20 hrs in micro-cultures of 200 µl with increasing arabinose 
concentrations (0, 0.025, 0.05, 0.1 and 0.2%), for the induction of the PBAD 
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promoter. Growth cultures were monitored in real-time by absorbance 
measurement at 600 nm (OD600).  
 
Western-Blot analysis 
Overnight cultures of PAO1/pHERD28T-TgpA-His, PAO1/pHERD28T-
C404A-His and PAO1/pHERD28T in LB media supplemented with 300 µg/ml 
trimethoprim (Tmp) were diluted to OD600 of 0.05, incubated at 37°C until OD600 
of 0.4-0.6 and induced with 0.1% arabinose. A parallel culture of each strain was 
grown without the addition of arabinose. After two hours induction, the cells were 
harvested at 7000 rpm for 10 min at 4°C and the pellet from 100 ml of culture was 
resuspended in 1 ml of lysis buffer (10 mM Tris-HCl pH 7.8, 20 μg/ml RNAse and 
DNAse, 1 mM PMSF, 0.2 mg/ml lysozyme) and passed through a French press 
for cell disruption. The lysate was centrifuged at 5000 rpm for 20 min at 4°C and 
supernatant was ultracentrifuged at 37,000 rpm for 1 h at 4°C. The pellet, 
corresponding to the total membrane fraction, was resuspended in 200 μl of Tris-
HCl pH 7.8. Ten microliters of the samples with no arabinose and of the samples 
induced with 0.1% arabinose diluted 1:10 were analysed on SDS-PAGE. For 
Western blot analysis, specific monoclonal anti-His antibodies (Roche®) in 0.05% 
PBS-T were used.  
 
Quantitative RT-PCR analysis 
Total RNA was purified with a Total RNA Extraction kit (RBC Bioscience). cDNA 
was generated by incubating 1 μg of RNA with Superscript II Reverse 
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Transcriptase (RT) (Invitrogen), 100 pg of random primers and buffer supplied by 
the manufacturer for 50 min at 42°C. RT was inactivated by incubation at 70°C 
for 15 min. As a control of DNA contamination in the subsequent quantitative RT-
PCR (qRT-PCR) analysis, reactions were also run without RT. qRT-PCR 
amplifications were performed in duplicate reactions of 15 μl in tubes filled with 
iQTM SYBR Green Supermix (Bio-Rad) and 300 nM of each primer (see below) 
and run in an iCycler Real-Time PCR machine (Bio-Rad) as follows: 1 cycle at 
95°C for 10 min, 50 cycles at 95°C for 15 s and 60°C for 40 s. The calculation of 
the relative expression of the tgpA gene from plasmid pHERD28T versus the 
empty vector was performed as described by the 2-ΔΔCT method (Livak and 
Schmittgen, 2001), normalizing first mRNA amounts to 16S ribosome RNA (ΔCT) 
and relating the ΔCT in the TgpA wt and C404A mutant ectopically expressed to 
the chromosomal copy (ΔΔCT) (PAO1-pHERD28T Empty vector). To confirm 
PCR specificity, the PCR products were subjected to melting curve analysis in a 
temperature range spanning 55-95°C with 1 cycle at 55°C for 50 s and 80 cycles 
at 55°C for 10 s set with 0.5°C increments after the first cycle.  
The primer pairs used for qRT-PCR were: 
tgpA 5’-CGAAAGCGCTCTGCTGCAA-3’/ 5’-TCTTCGCAGTGGTGGTGGG-3’ 
16S 5’-TGTCGTCAGCTCGTGTCGTGA-3’/ 5’-ATCCCCACCTTCCTCCGGT-3’ 
 
2.2 Complementation assay 
TgpA wild type (wt) and mutant C404A were tested for their ability to 
complement a glucose-mediated down-regulation of the chromosomal tgpA gene 
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in the PAO1 PrhaB::tgpA strain (Milani et al., 2012), when expressed from the 
ectopic vectors pHERD28T-TgpA or pHERD28T-TgpA-C404A. For the 
complementation assays, pHERD28T-TgpA and pHERD28T-TgpA-C404A were 
moved from E. coli JM109 to the conditional mutant PAO1 PrhaB::tgpA strain by 
triparental mating as described previously (Milani et al., 2012). Exconjugants 
PrhaB::tgpA clones were selected on M9 minimal medium plates supplemented 
with 0.2% citrate (M9-citrate), 60 µg/ml gentamicin (Gm), 0.2% rhamnose and 300 
µg/ml Tmp. This procedure generated the strains PAO1 PrhaB::tgpA/pHERD28T-
TgpA and PAO1 PrhaB::tgpA/pHERD28T-TgpA-C404.  
 
For both PrhaB::tgpA/pHERD28T-TgpA and PAO1 
PrhaB::tgpA/pHERD28T-TgpA-C404, the conditional growth was assessed after 
an overnight growth at 37°C in M9-citrate supplemented with 60 µg/ml Gm, 300 
µg/ml Tmp and 0.2% rhamnose. An aliquot of the overnight culture was 
centrifuged and the bacterial pellet was washed three times with sterile PBS, and 
diluted to an OD600 of 10-6 in fresh M9-citrate with appropriated antibiotics (60 
µg/ml Gm and 300 µg/ml Tmp) and supplemented either with 0.2% rhamnose or 
1% glucose. 200 µl of the different cultures were grown at 37°C with stirring and 
monitored in real time by OD600 measurement in microtiter reader (TECAN) for 20 
hrs.  
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2.3 Expression and purification of TgpA periplasmic domain. 
TgpA periplasmic domain (residues 180-544) was expressed in E. coli 
BL21CodonPlus (DE3) - RIPL (Agilent; chloramphenicol (Cm) resistance) as N-
terminally (His)10-tagged proteins, from plasmid p2N (PRIMM srl.; ampicillin 
(Amp) resistance). The cells were grown at 37°C in 2 l of LB medium containing 
100 µg/ml Amp and 34 µg/ml Cm, to an OD600 of 0.6. After induction with 1 mM 
isopropyl β-D-thiogalactopyranoside (IPTG), the incubation temperature was 
lowered to 17°C and cells were grown for 16 hours. Cells, harvested by 
centrifugation, were resuspended in lysis buffer (1x Phosphate buffer saline 
(PBS), 1% Triton, 5 mM MgCl2, 0.25 mg/ml lysozyme, 20 µg/ml DNase, 1µg/ml 
Pepstatin A, 0.5 mM AEBSF and 1 tablet of complete Protease Inhibitor 
(Roche®)), lysed with a cell disruptor at 27 KPSI, and the soluble fraction was 
collected after centrifugation at 15,000 rpm for 1 h at 4°C (Beckman JA20).  
 
The protein purification was performed at 4°C, using a Fast Protein Liquid 
Chromatography (FPLC) apparatus (ÄKTA system – GE Healthcare). After Ni-
IMAC column (HisTrapTM FF crude 5 ml, GE Healthcare) equilibration with Buffer 
A (20 mM Phosphate buffer pH 7.5, 500 mM NaCl, 0.5 mM AEBSF and 1 tablet 
of complete Protease Inhibitor Roche®), the soluble cell extract was loaded at 1 
ml/min and eluted at 250 mM imidazole. The protein was then loaded (1 ml/min 
flow-rate) on a SuperdexTM 75 column (GE Healthcare), previously equilibrated 
with Gel Filtration (GF) Buffer (20 mM Tris-HCl pH 7.5, 500 mM NaCl, 20 mM 
Imidazole, 0.5 mM AEBSF and 1 tablet of complete Protease Inhibitor Roche®). 
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The purified protein was concentrated up to 8 mg/ml using a centrifugal filter unit 
(10 kDa cut-off, Millipore).  
 
2.4 Crystal structure TgpA periplasmic domain. 
 Microbatch crystallization experiments on TgpA periplasmic domain (6 
mg/ml) were assembled with an Oryx-8 crystallization robot (Douglas Instruments, 
East Garston, UK), with 0.3 µl droplets containing 66/34% of the 
protein/precipitant solutions, covered with Al's oil. Crystals were obtained after 48 
hours at 20°C, in 0.8 M NaH2PO4, 0.8 M KH2PO4, and 0.1 M Na HEPES pH 7.5. 
Before collecting crystals for flash freezing in liquid nitrogen, about 0.1 µl glycerol 
was added to the crystal drop as cryoprotectant. The TgpA native crystals 
diffracted to a maximum resolution of 1.6 Å using synchrotron radiation at beam-
line ID30a3 at the European Synchrotron Radiation Facility (ESRF-Grenoble, 
France). Additional crystals ((NH4)H2PO4 0.7 M, 0.1 M Na HEPES pH 7.2) were 
selected for soaking with mercury derivatives. The crystals were soaked in a 
stabilizing solution ((NH4)H2PO4 0.7 M, 0.1 M Na HEPES pH 7.6) with 5 mM 
ethylmercurithiosalicylic acid sodium salt for 60 min, then washed (in stabilizing 
solution) and transferred into a cryoprotectant solution ((NH4)H2PO4 0.7 M, 0.1 M 
Na HEPES pH 7.6, glycerol 25%) and flash frozen. TgpA derivative crystal 
showed a nice absorption peak for mercury at 12.3 keV (1.008 Å) and diffracted 
to a maximum resolution of 1.8 Å at beam-line BM14U (ESRF-Grenoble, France). 
For both native and derivative crystals, X-ray diffraction data were indexed and 
scaled using XDS (Kabsch, 2010) (Table 1).  
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 The three-dimensional structure of TgpA was solved using the SAD 
method based on the mercury derivative (X-ray wavelength 1.00775 Å) using the 
program package SHELXC/D/E (Sheldrick, 2010) within the CCP4i interface 
(Potterton et al., 2003). Briefly, SHELXC detected an anomalous signal up to ~1.9 
Å; SHELXD (at 2 Å resolution) found 6 possible heavy atoms sites (CC All/Weak 
42.8/25.1, CFOM 67.9, best 67.9, PATFOM 16.28), and SHELXE calculated the 
initial phases and performed density modification (FOM=0.582, Pseudo-free 
CC=63.71%). The obtained experimental electron density was then used to trace 
an initial protein model with ARP/WARP (Lamzin and Wilson, 1997). The single 
TgpA molecule present in the crystal asymmetric unit was then subjected to 
manual (program COOT (Emsley et al., 2010)) and constrained refinements using 
REFMAC5 (Steiner et al., 2003), and the partially refined model was used for 
molecular replacement to solve the structure of the native dataset (Vagin and 
Teplyakov, 1997). Additional refinements with BUSTER (Smart et al., 2012) and 
REFMAC5 were subsequently performed for both datasets. Data collection, 
refinement statistics as well as stereochemical quality of the two models are 
summarized in Table 1. Atomic coordinates and structure factors have been 
deposited in the PDB (Berman et al., 2000), with accession codes .... 
 
2.5 Cell wall peptidoglycans isolation  
A published method (Desmarais et al., 2014) with minimum modifications was 
followed for the isolation of cell wall peptidoglycans (PGN) from P. aeruginosa. 
Cells were harvested from an exponential phase culture (OD600 of 0.8) by 
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centrifugation, washed two times with phosphate-buffered saline (PBS). The final 
pellet was resuspended in 3 ml of PBS, slowly added to boiling 6% SDS solution 
and boiled for 2 h; the mixture was then stirred overnight at room temperature. 
Cell walls were recovered by ultra-centrifugation at 400.000 x g, washed six times 
with ultrapure water at room temperature and then digested with 100 μg/ml of 
Pronase E (Sigma - Aldrich) for 2 h at 60°C. The reaction was stopped with the 
addition of 200 μl of 6% SDS and incubation for 30 min at 100°C. Additional 
washes by ultra-centrifugation at 400.000 x g were performed until the excess of 
SDS was removed. The final cell walls were resuspended in 50 mM MOPS, pH 
7.0 and stored at -20°C.  
 
2.6 Insoluble peptidoglycan pulldown assay 
For PGN binding assay, we slightly modified a procedure already described 
(Wong et al., 2014). In a 50 μl reaction mixture, 50 μg of purified TG domain was 
added to increasing amounts of PGN (25, 50, 100, 200 and 400 μg) in the assay 
buffer: 50 mM Tris-HCl, pH 8, 1 M NaCl, 5 mM β-mercaptoethanol, 1% tween-20. 
The reaction was incubated for 30 min at 25°C, and then centrifuged at 10,500 g 
for 45 min. The supernatant was collected, and the insoluble PGN pellet was 
washed three times in assay buffer. Ten microliters of supernatant and 
resuspended pellet solution were analysed on a 10% SDS-PAGE gel. As a 
reaction control, three different proteins (BSA, DNAse (Sigma) and helicase from 
dengue virus) were used in reaction with the PGN at the same conditions as TG 
domain. A negative control was performed with 50 μg of each protein under the 
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same conditions but without PGN, to ensure that the proteins were not 
precipitating on their own.  
 
2.7 Cell wall binding affinity - Microscale thermophoresis  
To evaluate the binding ability of the TG domain to cell wall components, 
we used PGN isolated from both Bacillus subtilis (Sigma – Aldrich) and P. 
aeruginosa.  
Protein interactions with PGN were measured through Microscale 
thermophoresis (MST). The soluble fraction of the sacculi from P. aeruginosa and 
B. subtilis was separated from the insoluble portion by ultracentrifugation 
(15000g). With the dry weight of the insoluble fraction of the PGN it was possible 
to stablish that the 50% of the mixture remains soluble (5mg/ml). Serial dilutions 
of the soluble fraction were prepared to set a standard curve with the absorbance 
at 280nm (A 280nm) of each dilution. The curve was used to stimate a 
concentration of the soluble fraction of the isolated PGN from P. aeruginosa.  
 
With the hypothesis that the interaction between TG domain and the PGN 
was due to the glycans (N-Acetylglucosamine [GlcNac] and N-acetylmuramic acid 
[MurNAc]) present in each molecule of the muropeptide, we used the molecular 
weight of the disaccharide GlcNac - MurNAc (496.466g/mol) to calculate a 
hypothetical dissociation constant (Kd). 
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The TG domain and the helicase from dengue virus were labelled with the 
monolith NTTM Protein labelling Kit RED-NHS (NanoTemper technologies, 
Munich, Germany) to achieve a 1:1 molar ratio of labelled protein to dye. The 
concentration of labelled TG domain and helicase were constant at 75 nM, in 
thermophoresis MST buffer (50 mM Tris-HCL pH 7.4, 150 mM NaCl, 10 mM 
MgCl2, 0.05% Tween-20). Serial dilutions of the PGN were prepared in MST 
buffeer: PGN from P. aeruginosa varied from 0.125 mM to ∼7.6 nm, and higher 
concentration of B. subtilis were used to define better the curve, from 5 mM to 
∼150 nM. MST measurements were performed at 24°C on a Monolith NT.115 
instrument (NanoTemper Technologies) using Premium coated capillary. Binding 
curves were obtained from the thermophoresis, with MST power 60%.  
 
 
 91 
 
3. Results 
 
3.1 Cys404 in the periplasmic TG-like domain is critical for TgpA cell activity 
 TgpA is endowed with a periplasmic region harboring a structural domain 
predicted to belong to the transglutaminase-like superfamily (TG-like domain), a 
group of archaeal, bacterial and eukaryotic proteins homologous to animal 
transglutaminases (Makarova et al., 1999). The TG-like domain is characterized 
by the presence of a conserved catalytic triad Cys404-His448-Asp464. To assess 
whether the TgpA essential function (Milani et al., 2012) for P. aeruginosa viability 
resided in the TG-like domain, we generated a substitution of residue Cys404 with 
Ala (C404A mutant) in the full length protein, and evaluated the ability of such 
mutant to complement an induced down-regulation of the chromosomal tgpA 
gene in the P. aeruginosa conditional mutant PAO1 PrhaB::tgpA (Milani et al., 
2012).  
 
Frist of all, we evaluated the ectopic expression also in the absence of inducer 
arabinose using Western blot analysis (Fig. 1) and Real time PCR (Table 1). Cell 
cultures without / with arabinose (0.1%) were grown and the membrane fractions 
were used for the analysis. With a specific monoclonal anti-His antibody, a unique 
band around 70 kDa corresponding to TgpA-His (wt and mutant C404A) was 
detected (absence of the band in the empty vector) (Fig. 1). The presence of the 
band also in the absence of the arabinose inducer, both in the wt and the mutant 
C404A, provided evidence of the basal activity of the PBAD promoter. 
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Quantification of mRNA levels of the ectopically expressed TgpA wt and C404A 
mutant genes, relative to the chromosomal copy, was determined by quantitative 
Real-Time PCR on total RNA, isolated from the growth in the absence and 
presence of 0.1% arabinose (Table 2). A level of basal activity of the PBAD 
promoter was confirmed by this analysis. 
 
We then evaluated whether ectopic expression of TgpA wt or C404A mutant could 
per se influence the growth of P. aeruginosa (PAO1 strain) under five 
concentrations of arabinose (0, 0.025, 0.05, 0.1 and 0.2%). As shown in Fig. 2, 
the ectopic expression of TgpA wt and C404A mutant resulted in an arabinose 
dose-dependent negative influence on P. aeruginosa growth. The negative 
effects, evident also in the absence of arabinose (Fig. 2), can be explained with 
the basal activity of the PBAD promoter.  
 
The two vectors pHERD28T-TgpA or pHERD28T-TgpA-C404A were then 
transferred to a conditional mutant carrying a chromosomal tgpA gene under the 
control of the PrhaB promoter (Milani et al., 2012). This strain is usually maintained 
in the presence of rhamnose (0.2%) that induce the expression of tgpA. However, 
the PrhaB promoter can be strongly down regulated by glucose addition in the 
medium. Consequently, PAO1 PrhaB::tgpA is unable to grow in the presence of 
glucose unless functional TgpA is ectopically expressed (Milani et al., 2012). 
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As shown in Fig. 3A, TgpA wt expressed by the basal activity of the PBAD promoter 
(Ara 0%) is already able to complement the forced repression of the PrhaB 
promoter by 1% glucose. In fact, PAO1 PrhaB::tgpA is able to grow with 1% glucose 
as well as in the permissive condition of 0.2% rhamnose. Differently from TgpA 
wt, the basal expression of the C404A mutant (Ara 0%) does not complement the 
forced repression of wt protein (Fig. 3B). Together, these results show that 
Cys404 is critical for the essential function of TgpA.  
 
3.2 Crystal structure of the periplasmic domain of TgpA.  
 During the expression and purification, the recombinant TgpA periplasmic 
domain was susceptible to proteolytic cleavage, evident by the presence of two 
bands around 40kDa. Such feature suggests a disordered nature of this part of 
the sequence. Mass analysis confirmed the loss of more than 20 amino acids at 
the C-ter end; although it was not possible to identify a precise site of cleavage, 
the produced peptides indicated different cleavage sites around Tyr499 (Fig S1 
in the supplementary information).  
 
 The experimental electron density allowed to model the protein periplasmic 
domain between residues Val195 and Leu482, that is ~17 amino acids upstream 
the cleavage region. The domain is folded in a tripartite globular structure (with 
average dimensions 50x45x30 Å3) resembling a heart built by two sub-domains 
(right and left ventricles) linked by a central antiparallel beta sheet composed of 
four strands (the septum). The right ventricle (mostly formed by the N-terminal 
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portion of the domain) is primarily composed of β strands, with a major solvent 
exposed antiparallel β sheet (composed of 6 strands). On the contrary, the left 
ventricle that, together with the septum contains the conserved catalytic triad, is 
mainly composed of alpha helices (Fig. 4). Interestingly, N-and C-terminal ends 
of the domain are located on the same side of the protein, in agreement with its 
internal membrane anchoring.  
 
A structure based homology search, over the whole domain and through 
the DALI server (Holm and Rosenstrom, 2010), identified two putative cysteine 
proteases (pdb-id 3ISR, Z=9.8 id. 18%; and pdb-id 3KD4, Z=8.7 id. 17%) from 
gram-negative bacteria, and the transglutaminase coagulation factor XIII (pdb-id 
3KD4, Z=6.4 id. 22%). A new search for similar folds using the CATH server 
(http://www.cathdb.info) (Sillitoe et al., 2015) identified the pantoate-beta-alanine 
ligase functional family (Pantothenate synthetase 2, CATH-ID 3.30.1300) for the 
C-terminal domain, and the immunoglobulin-like domain or Cellulose-binding 
family II for the N-terminal extension, respectively.  
 
 Limiting the structural search to the N-terminal portion of the domain 
(residues Val195 to Ala323) yielded structural similarity to different carbohydrate 
binding domains, such as the chitin binding domain (chitinase, pdb-id 5DHE, 
Z=2.8, 13% identity (Hanazono et al., 2016)) and the xylan binding domain 
(xylanase, pdb-id 1XBD, Z=2.7, 7% identity), pointing to a possible involvement 
in binding to the cell wall peptidoglycan. In particular, the chitinase domains 
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(ChBD2 and ChBD3) belong to the carbohydrate binding domain family-II type 
(IPR001919, CBM2). CBM2 is further classified into two subfamilies according to 
substrate specificities: CBM2a that binds cellulose, and CBM2b interacting 
specifically with xylan. Like other CBM domains CBM2 is a beta-sheet domain 
containing a planar surface able to bind its ligand(s) via a hydrophobic strip of 
aromatic residues.  
 
 A DALI structural search based on residues corresponding to right ventricle 
yielded again a protein involved in sugar binding (GH52 Beta-D-xylosidase; pdb-
id 4RHH, Z=3.4, 7% identity) that hydrolyses Beta-D-xylans. Conversely, 
searching for structural homologs of the C-ter portion of the protein with CATH 
(http://www.cathdb.info) we found (in addition to Pantoate--beta-alanine Ligase) 
3.30.460.10 Beta Polymerase, domain 2 and v-type ATP synthase like domains. 
 
Active site 
 
 Cys404 has been shown above to be critical for the essential activity of 
TgpA in P. aeruginosa growth. Cys404 is hosted in the C-terminal portion of the 
periplasmic domain, forming a typical catalytic triad with His448 and Asp464. 
While His and Asp side chain positions are restrained by a mutual H-bond (2.8 Å), 
the Cys side chain is not involved in any electrostatic interactions with other 
residues or water molecules (shorter distance 3.4 Å with main chain nitrogen of 
Ala449). The environment around Cys404 is characterized by the presence of 
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several aromatic and polar residues, e.g. Tyr380, Phe403, Arg473, and Thr466. 
Around His448 a network of H-bonds is found involving (besides Asp464) 
residues Thr466, Arg473 and Tyr380 bridged by two water molecules and linked 
to the main chains of residues Phe445 and Ala447. 
 
 The active Cys404 is buried inside the protein domain (at about 10 Å from 
the surface) but it may become accessible when the right substrate is present or 
in the full length protein. Such feature is supported by analysis of the Hg derivative 
structure, where, in order to accommodate the ethyl-mercury moiety linked to 
Cys404, Phe403 side chain rotates by ~135° around its 1 angle, widening the 
active site cavity. Moreover, in the heavy atom bound structure the C-ter end of 
the protein (478-480) displays a conformational change (starting from Gly477), 
and becomes more mobile (first defined amino acid in the electron density is 
Leu478 vs. Ala483 in the native structure), yielding a wider entrance path to the 
active site. Interestingly, together with the ethyl-mercury sustituent, a phosphate 
ion is present within the active site cavity, H-bonded to His268 and Tyr200, with 
electroststic compensation by Hg and Arg473.  
 
A different smaller cavity (N-terminal helix amino acids 205-212) is present in the 
native structure, where a phosphate ion (3.9 Å from the Sulphur of Cys404) is H-
bonded to the main chain N-atoms of Gly205, Ile207, Ala208 and Ala405, and to 
the side chain of His406. The native and the heavy atom bound structures 
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together allow to propose a gating mechanism regulating substrate accessibility 
to the active site that would involve: 1. C-terminal helix. 2. N-ter helix, 3. Phe403 
(Fig. 5).  
 
 Analysis of the overall geometry of the active site residues using the 
LabelHash server (Moll et al., 2011) identified structural homology with the active 
site of a Cys endopeptidase acting on muropeptides (Xu et al., 2009). Therefore, 
all the structure-based analyses point to a protein involvement in muropeptide 
binding and cell wall remodelling. 
 
3.3 . TgpA Binding to Peptidoglycan 
Structural analysis restricted to the N-terminal portion of the protein (from 
Val195 to Ala323) displays some homology with two carbohydrate binding 
domains (ChBD), like chitin binding domain, fitting with the families ChBD2 and 
ChBD3, that bind chitin and cellulose. 
 
Cellulose, chitin and peptidoglycan (PGN) are major polymers in living organisms, 
consisting of a long chain of carbohydrates linked with β-1,4 glycosidic bonds. 
Principles and regulatory mechanism of the enzymes involved in metabolism of 
these polymers are still unknown; however, there is growing available structural 
and biochemical information on how synthesis, chemical modifications and 
hydrolysis processes may occur.  
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In bacteria, there are well-characterized domains that bind cell wall components, 
tightly related with enzymes that participate in the peptidoglycan degradation and 
remodelling.  
 
Since the major component of the bacterial cell wall is a complex polymer formed 
by glycan chain cross-linked by peptide stems, we investigated the hypothesis 
that the TgpA TG domain might be able to bind to PGN. To this end, we performed 
PGN pulldown assays; proteins binding the insoluble PGN would coprecipitate 
with them in the pellet after centrifugation. SDS-PAGE was used to analyse the 
amount of PGN bound proteins. 
 
Pulldown experiments (Fig. 7) shows that in the presence of increasing 
concentrations of PGN, the amount of TG domain present in the pellet increased, 
in keeping with the TG capability to bind the PGN from P. aeruginosa. On the 
contrary, the helicase from Dengue virus, used as a negative control, showed no 
detectable PGN binding. Similar negative results were obtained with both BSA or 
DNase (data not shown). 
 
3.4 . MST measurements 
To further analyse the binding affinity between TG domain and PGN, we 
assessed the specificity of the interaction through Microscale thermophoresis - 
MST. For this purpose, we compared the binding capacity of the TG domain 
towards the sacculi from both B. subtilis and P. aeruginosa. Negative controls 
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were performed with helicase from Dengue Virus under the same conditions.  
We observed that the TG domain has the ability to bind both PGN from P. 
aeruginosa and B. subtilis (Fig. 8), with affinity in the μM range (estimated with 
the hypothesis that the binding is given by the interaction with the glycans 
presents in each molecule of muropeptide; see Materials and Methods). However 
the TG domain shows slightly greater affinity for the PGN from P. aeruginosa. The 
helicase does not bind the PGN from PAO1 but it binds the PGN from B. subtilis 
with a Kd in the millimolar range, i.e. around 10 times lower affinity than the value 
observed for TG domain (Table 3). 
 
4. Discussion 
 Nowadays, P. aeruginosa is considered a public health risk due to its 
ability to develop resistances to multiple classes of antibiotics. Urgent and novel 
strategies to discover new antibiotics are required and the study of essential 
genes has proved to be an interesting strategy for the identification of important 
antimicrobials targets. 
 
TgpA is an essential protein for the viability P. aeruginosa, proven through 
insertional and conditional mutagenesis (Milani et al, 2012) and is composed of 
an N-terminal domain with 5 transmembrane (TM) helices (residues 11-321 
belonging to the DUF3488 superfamily), a periplasmic domain (residues 180-
548), and an additional TM helix (residues 549-567) terminating into a small C-
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terminal cytoplasmic domain (residues 582-638 belonging to the DUF4129 
superfamily).  
 
Our structural investigation shows that the periplasmic portion of TgpA is 
composed of two subdomains linked by a central β-sheets (the septum): the N-
ter domain, rich of β-strands, likely endowed with regulatory and/or substrate-
binding activity, and the α-helices at C-ter domain, hosting a conserved catalytic 
triad likely involved in specific enzymatic activity. In keeping with these 
hypotheses, using inducible expression and complementation experiments of the 
wt TgpA and the Cys404Ala mutant, we demonstrated the crucial the role of 
Cys404 for the (so far unknown) TgpA activity required for bacterial growth.  
 
 Considering the periplasmic localization of the protein and the evidence 
that the N-ter subdomain is structurally linked to different carbohydrate binding 
domains, our structural results suggest a probable involvement of the protein in 
cell wall (re)modelling. Accordingly, we proved that the TG domain is able to 
interact with PGN (pulldown experiments) with an estimated affinity in the uM 
range (MST experiments). Such degree of affinity was previously described by 
Wong et al, 2013, with the evaluation of the affinity of the LysM domain for 
different fragments of PGN, also estimated in the low macromolar range (μM). 
LysM is a well characterized carbohydrate-binding domain with affinity for GlcNac 
polymers and often associated with proteins involved in PGN synthesis or 
remodeling. Although the carbohydrate binding module at the N-terminal end of 
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the TG domain does not share homology with LysM or other already known 
domains that binds the bacterial PGN, the mechanisms of bacterial PGN 
recognition and regulatory mechanisms of the enzymes involved in its metabolism 
are still largely unknown. Further specific analysis must be done in order to identify 
the residues involved in the interaction with the PGN, in addition to the exploration 
of other possible substrates of the protein presents in the cell wall. 
The motility of the domain C-ter end, suggested by analysis of the crystal 
structures, could be related to tuning of the protein activity via substrate(s) 
recognition, allowing the opening of the active site cleft toward the solvent only 
when the right substrate is present. In particular, the two structures available 
suggest a gating mechanism regulating the substrate accessibility to the active 
site involving: N and C-ter portions of the domain, together with Phe403. Since 
the terminal ends of the domain are linked to the inner transmembrane portions 
of the enzyme, protein-membrane interaction might play a role in regulation of 
substrate accessibility and/or enzymatic activity. Furthermore, a regulative role 
might be also played by the small C-ter cytoplasmic domain of the protein. Finally, 
the observed binding of phosphate ions might suggest a possible role for 
phosphorylated substrates. 
 
All the microbiology, structural and biochemical data reported contributed to start 
unravelling the function of a new protein essential for P. aeruginosa viability, which 
represents a valuable target for the development of novel antibacterial therapies. 
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Fig. 1 Western Blot analysis of the ectopic expression of the TgpA wt and 
C404A full-length proteins in absence and presence of arabinose. 10 ul of 
total membrane fraction from the growth under each condition were loaded onto 
12% SDS-PAGE. Samples induced with 0.1% Ara are diluted 1:10 with respect to 
the samples without arabinose. MW = Molecular weight marker. 
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Fig. 2 Effects of ectopic expression of TgpA wt and mutant C404A on P. 
aeruginosa growth. The effects on growth were evaluated relative to PAO1 
carrying the empty vector pHERD28T under five different concentrations of 
arabinose (0, 0.025, 0.05, 0.1 and 0.2%) for the induction of the PBAD promoter. 
For each culture, the OD600 value after 16 hrs of growth (i.e. the onset of the 
stationary phase) was plotted with the corresponding concentration of arabinose. 
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Fig. 3 Tests of complementation of a glucose-mediated down-regulation of 
the chromosomal tgpA gene in PAO1 PrhaB::tgpA. PAO1 PrhaB::tgpA strains 
carrying pHERD28T-TgpA wt (A), pHERD28T-TgpA-C404A (B) were grown in 
micro-cultures of 200 µl with the indicated concentrations of arabinose, rhamnose 
and glucose. Cultures growth was monitored in real-time by absorbance 
measurement at 600 nm (OD600). 
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Fig. 4 Blue right ventricle; green septum; red left ventricle; catalytic triad as yellow 
sticks 
 110 
 
 
Fig. 5 Proposed substrate gating mechanism: entrance of the substrate from C-ter 
helix and Arg473, exit of the product toward N-terminal helix. Gating controlled by 
the position of Phe403. 
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Fig. 6 strictly conserved residues in an alignment done with members of the 
gammaproteobacteria class (excluding pseudomonadales order) (lower seq. 
identity 45%) Active site cluster red, structural cluster blue, isolated residues 
(orange) 
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Fig. 7 Pulldown experiments with insoluble PGN. The binding capacity of the (A) 
TG domain and (B) Helicase were assayed by pulldown assay with increasing 
concentrations of insoluble PGN from P. aeruginosa. The lanes are labelled as 
follows: MW = Molecular weight marker, P = Pellet, S = Supernatant. 
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Fig. 8 TG domain-PGN interaction analyzed by MST. The TG domain – PGN 
interaction was monitored by titrating PGN form B. subtilis from 5 mM to ∼0.1 nM 
against 75 nM of TG domain labelled with the Kit RED-NHS (NanoTemper 
technologies, Munich, Germany). The changes of the fluorescent thermophoresis 
signals were plotted and Kd values were determined using the NanoTemper 
analysis software, through non linear curve fitting.  
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Table 1. X-ray data-collection and refinement statistics 
 
Data collection TgpA Hg derivative TgpA native 
Beam line & 
wavelength (Å) 
ESRF BM14U  
1.00775 Å 
ESRF ID30a-3  
0.96770 
Space group P43212 P43212 
Unit-cell parameters (Å) a=b=72.5; c=157.5 a=b=71.6; c=164.3 
Molecules in a.u. 1 1 
Resolution (Å) 48.7 – 1.8 43.5 – 1.6 
Mosaicity (°) 0.2 0.2 
Unique reflections 74,217 (5,444)a 57,370 (4,156)b 
Completeness (%) 99.9 (99.1) 99.9 (100) 
Redundancy 7.1 (3.8) 7.5 (7.8) 
Rmeas† (%) 9.1 (127.5) 6.4 (146.8) 
CC(1/2) (%) 99.9 (42.5) 99.9 (73.9) 
Average I/σ (I) 15.5 (1.1) 17.6 (1.7) 
Final model   
R factor‡/Rfree§ (%) 15.4/19.0 15.4/18.8 
r.m.s. bonds (Å) 0.024 0.024 
r.m.s. angles (°) 1.21 1.21 
Average protein B 
fac.(Å2) 
...b ...b 
Residues in most 
favored regions (%) 
97% 97% 
Residues in additionally 
allowed regions (%) 
3% 3% 
PDB-ID ... ... 
 
Values in parentheses are for the highest resolution shell: a(1.85-1.80), b(1.64-1.60). 
† Rmeas = (Σ (n/(n-1) Σ |I - (I)| )/ Σ I x 100, where I is intensity of a reflection and (I) is its average 
intensity.  
‡ Rfactor = Σ |Fo - Fc| / Σ |Fo| x 100.  
§ Rfree is calculated on 5% randomly selected reflections, for cross-validation. 
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Table 2. Relative mRNA levels of ectopically overexpressed TgpA wt and C404A 
mutant 
 
Strain OD600 0% Ara 0.1% Ara 
PAO1-pHERD28T 0.8 1* 1 
PAO1-pHERD28T-TgpA wt 0.8 16 544 
PAO1-pHERD28T-C404A 0.8 11 363 
 
*Values represent 2-ΔΔCT values of the ectopic expression of tgpA mRNAs 
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Table 3. Binding constants for PGN ligands. The equilibrium dissociation constants (Kd) are 
given in μM. NS: Not Significative 
 
 Kd (μM) 
P. aeruginosa B. subtillis 
TG domain 39± 2 210 ± 4 
Helicase NS 1800± 390 
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Supplementary information  
 
Mass spectrometry analysis 
Bands of interest were excised from SDS-PAGE and digested with trypsin and other 
peptidases, and analysed with LC-MS in the Protein Microsequencing Facility (PROMIFA- 
San Raffaele Scientific Institute-Milan).  
  
 
Fig S1. Mass spectrometry analysis of the two bands obtained during the TG domain 
purification. In Red are highlighte all the peptides generated by tripsin digestion and 
identified with mass analysis. In Green are highlithed those peptides generated by digestion 
with other peptidases different from trypsin. 
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PART  III 
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F. Preliminary results 
 
F.1 TgpA In silico docking 
Molecular docking has become an increasingly important tool for drug discovery. 
This approach can be used to model the interaction between a small molecule 
and a protein at the atomic level, which allows characterizing the behaviour of 
small molecules in the binding site of target proteins as well as to elucidate 
fundamental biochemical processes.  
 
A search was maid through molecular docking ligand-protein complexes by 
exploring the conformational space of a library of ligands within the active site of 
the TG domain. A scoring function was used to approximate the free energy of 
binding between the protein and the ligand in each docking pose. Docking and 
scoring produced a series of ranked compounds, with which were subsequently 
evaluated in vivo. 
 
 
 
Figure F1. Representation of putative inhibitory compounds found during In silico docking, located 
inside the catalytic core of the TG domain structure. 
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In the TG domain 3D structure it is possible to identify a putative ligand-binding 
cavity displaying open or closed structure, regulated by the conformation of the 
C-terminal tail of the domain. Using the 3D structure of the protein in the open 
state (Hg bound) it was analysed in silico a medium size library of commercially 
available compounds (Hit2lead with 30,000 molecules) identifying eight potential 
binders with predicted Ki in the nM range. 
 
The library was first analysed with the program AutoDock Vina (fast screening) 
exploring a protein region around Phe403 (with extension of 23 Å in every 
direction) to extract the top molecules (161 molecules, 0.5% of the library). In a 
second run the chosen compounds have been ranked more accurately with the 
program AutoDock (slow screening) identifying the best eight molecules that are 
listed in Table F1. 
 
For in vivo evaluation, overnight cultures of PAO1 and E. coli strain M1655 were 
diluted in LB 50% to OD600 10-6 and inoculated in microtiter wells with serial 
dilutions of each compound per triplicated, starting from 100 μM to 0.05μM.  
Culture growths were monitored in real-time by absorbance measurement at 
OD600 for 20 hrs and the percentage of inhibition was calculated considering 100% 
the growth of the control PAO1 and E. coli M1655 in the absence of compounds. 
 
The compound #8 could not be evaluated because it was not soluble. The other 
seven compounds tested in PAO1 and in E. coli M1655, did not show a significant 
inhibition; none of them showed an inhibition of growth higher than 50% (Table 
F1). 
 
The percentage of inhibition observed in E. coli M1655, generally higher than that 
observed in PAO1, suggests that the inhibition might not be specific to the function 
that TgpA fulfills in PAO1, since E. coli M1655 shares no homologs with TgpA. 
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The compound #2 shows inhibition of around 17% in P. aeruginosa, which is not 
trivial for a first screening. 
 
In order to continue with the search for possible inhibitory molecules of the TgpA 
activity, which consequently inhibit the growth of P. aeruginosa, the search and 
evaluation of new compounds must be performed. 
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Table F1. 2D chemical structures of the eight top-scoring compounds found 
during in silico docking of the TG domain, and its percentage of inhibition in PAO1 
and E. coli strain M1655. NT: Not tested  
 
Compund Ki (nM) Structure 
Percentage (%) of inhibition 
PAO1 E. coli M1655 
 
 
1 
 
25.2 
 
0 8±0.07 
 
 
2 
 
9.3 
 
17±0.07 14±0.09 
 
 
3 
 
348 
 
13±0.06 29±0.1 
 
 
4 
 
42.3 
 
10±0.04 25±0.1 
 
5 
 
33 
 
10±0.03 21±0.05 
 
6 
 
375 
 
5±0.04 17±0.05 
 
7 
 
343 
 
3±0.03 23±0.04 
 
8 
71.2 
 
        NT            NT 
 
 
